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 Background: Breast cancer mortality is higher for black and younger women. 
Understanding breast cancer mortality disparities by race and age is complex due to disease 
heterogeneity, comorbid disease, and the range of factors influencing access to care and delays in 
treatment. This dissertation identified patterns of socioeconomic (SES), access to care and tumor 
factors by race and age and examined the association of these patterns with treatment initiation 
and duration by treatment modalities.  
 Methods: Distributions of SES and comorbidity factors in the Carolina Breast Cancer 
Study Phase III (CBCS3) cases were compared to those of North Carolina women in the 2010 
Behavioral Risk Factor Surveillance Study. Using latent class analysis of CBCS3 data, we 
identified covariate patterns by SES (i.e., income, education, insurance, rurality, comorbidities), 
barriers to care, and tumor characteristics (i.e., tumor size, node, grade, hormone receptor status) 
and examined their associations with race and age using multinomial logistic regression. We 
estimated delay in treatment initiation (>60 days) and duration (measured in quartiles) by 
modality (surgery alone or combination of surgery and radiation and/or chemotherapy), in 
association with race, age and multivariable latent class composites and individual access factors. 
 Results: Major SES and comorbidity patterns in CBCS3 participants were generally 
similar to patterns in the state. In CBCS3, compared to white women, black women had lower 
SES, more barriers to care, and several aggregated tumor aggressiveness features. Of 2,841 
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women with stage I-III disease, 32% of younger black women were in the highest quartile of 
treatment duration compared to 22% of younger white women. Race/age differences in delayed 
treatment initiation were modest; however, treatment duration was longer for black women and 
was compounded by lower SES and increased barriers to care. Within the same treatment 
modality, prolonged treatment duration was more likely in black than white women. 
Transportation issues were associated with prolonged treatment duration among women whose 
treatment included radiation. 
 Conclusions: Black and younger women were more likely to experience barriers to care 
and aggregated tumor characteristics. Treatment duration was prolonged among black women 
and women with lower SES and increased barriers to care among most treatment modalities. 
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CHAPTER 1: BACKGROUND 
1.1 Overview: breast cancer disparities in the U.S. 
 Among U.S. women, breast cancer is the most commonly diagnosed cancer, the second 
most common cause of death from cancer and the leading cause of premature mortality, 
measured by total years of life lost (1). Currently, the average lifetime risk of a woman 
developing breast cancer is approximately 12%, annually totaling over 250,000 new cases and 
40,000 deaths from breast cancer (2, 3). Particularly, disparity in breast cancer incidence 
between young black and white women is widening. Breast cancer is a complex and 
heterogeneous disease, and can greatly differ according to exposures, socioeconomic 
(SES)/social position (SEP), age, race, tumor characteristics and a host of factors (4). 
Additionally, treatments for breast cancer vary and are dependent on these factors. Thus, a 
greater understanding of how race and age relate to tumor characteristics and SES, comorbidities 
and access to care factor patterns can further shape the interpretation of future studies of breast 
cancer outcomes. Table 1 provides a brief overall summary of risk factors for breast cancer 
incidence. 
1.1.1 Age disparities in breast cancer  
 The single strongest risk factor for breast cancer is age. Increasing age increases a 
woman’s risk of breast cancer, where 79% of all new breast cancer cases occur after age 50 (5). 
The cumulative percent of breast cancer incidence in women under age 40 is approximately 7%, 
less than 3% before age 35 and 1% before age 30 (6), and the epidemiology less known. 
Younger-onset breast cancer is usually more aggressive compared to breast cancer occurring 
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later in life (7-10). The poorer prognosis in younger-onset breast cancer is associated with more 
aggressive treatments and with poorer survival, even after controlling for certain patient and 
tumor characteristics and treatment receipt (6, 11, 12). Younger-onset breast cancer is 
statistically significantly associated with a higher stage and grade at diagnosis compared to later 
onset breast cancer (7). Additionally, women aged 35 years or less have greater distant 
metastases rates compared to older patients (13). Age younger than 35 years is a statistically 
significantly predictor of recurrence, after adjusting for clinical, pathologic features and 
treatment-related variables (RR = 1.70 [95% CI 1.18-2.43])(13).  
Age at diagnosis is also reflects a number of demographic and other factor differences. 
For example, mammographic screening is not typical in women under 40 years old. The majority 
of these women self-detect the breast cancer, when the tumor has progressed to a palpable size, 
which leads to delays in diagnosis, and may lead to poorer outcomes (14). Studies have 
evaluated known factors associated with younger or premenopausal women. These factors will 
be described in the following sections, such as age of first pregnancy, parity, age at menarche, 
oral contraceptive use, breastfeeding and body mass index (BMI) (15-17). Together, studies 
suggest that breast cancer in younger women is etiologically and clinically different than breast 
cancer in older women. 
Despite what is known about age, it remains a complex factor, as it serves as a proxy for 
a host of know and unknown exposures that may lead to cancer; including genetic, modifiable 
and environmental exposures that are in flux across the life course (18). Thus, it is important to 
understand the underpinnings of how age is used as a variable in breast cancer outcomes studies 
as it relates to a wide swath of risk factors over time. Table 2 provides a brief overall summary of 
risk factors for breast cancer incidence, young vs. older age. 
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1.1.2 Black-white disparities in breast cancer 
Breast cancer is the second most common 
cause of cancer death among black women (19). 
An estimated 6,310 deaths from breast cancer 
were expected to occur among black women in 
2016. Historically, black women in the U.S. have 
had lower incidence rates of breast cancer 
compared to white women, but higher death from 
breast cancer rates (5). Also historically, after 
adjusting for age, black women under age 40 have 
had a higher incidence rate compared to white women under age 40 (20). In more recent years, 
the trends in overall breast cancer incidence rates have increased in black women but not for 
white women. Breast cancer incidence between black and white women converged in 2012, 
which reflects the increased incidence for black women and stable rates for white women as seen 
in Figure 2 (5). 
Figure 1.1. Female breast cancer 
incidence rates by race/ethnicity, United 




Moreover, the complex patterns of breast cancer 
by race must also incorporate consideration of age. 
During the time period from 1992 to 2004, the incidence 
per 100,000 women-years among women under age 40 
was 16.8 among black women compared to 15.1 among 
white women (21). The rates were even more disparate 
in the under age 30 group. During this time period, black 
women had a 43% higher breast cancer mortality rate 
compared to white women (5). African American race 
remains a strong significant predictor of breast cancer 
among women under age 35 (RR = 2.66, 95% CI = 1.4, 4.9) (10, 22). Here, black women have 
greater than twice the incidence of invasive breast cancer and have greater than three times the 
mortality compared to young white women, in analysis of SEER data from 1990 to 1998 (23). 
Additionally, an incidence rate crossover effect between black and white women has been 
described.  Although incidence rates are lower for black women over age 40 compared to white 
women over age 40, age-specific incidence rates are higher for black women than white women 
younger than age 40. This incidence rate crossover, as illustrated in Anderson et al. is shown in 
Figure 3 (24).  
Black women report greater advanced stage of disease and more aggressive disease, patterning of 
SEP by race is important to understand the complex systemic effects on disease outcomes, It is crucial to 
understand how the differential factors influence of breast cancer risk. Further, to understand the 
impact it is necessary to understand the patterns of tumor characteristics and risk factor history 
among black women. However, there are few population-based studies that include enough black 
women to understand these patterns, stratified by age and race. Non-genetic breast cancer risk 
Figure 1.2. Age-specific incidence 
rates for breast cancer among black 
and white women in SEER 9, 1975 
to 2004. Anderson et al. 2008. 
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factors, such as SES, comorbidities, and lifestyle factors, among younger vs. older white and 
black women are reviewed below.  
1.2 Description of SES and comorbidity factors and breast cancer by age and race 
In general, compared to white women, black women have 1.) Worse non-modifiable 
factors such as familial history of disease, 2.) Less equitable harder-to-modify risk factors such 
as SES factors and reproductive factors and 3.) Poorer modifiable risk factors such as obesity and 
comorbid disease. Generally, in all these factors the patterns differential by race are remarkable; 
almost every indictor is associated with earlier onset of disease and more severe disease at all 
ages. Evaluating how these factors combine to contribute to racial disparity in breast cancer 
incidence is warranted. Differences in these factors among younger women and among black 
women have been investigated in a number of studies. The following sections will review the 
literature and will elaborate on 1.) What is known about the patterns of these factors by race and 
age, and 2.) How these patterns relate to differential risk of breast cancer outcomes.  
1.2.1 Socioeconomic position and breast cancer 
 Socioeconomic position (SEP) is one dimension of social stratification, referring social 
and economic factors (such as income, poverty, deprivation, wealth and education) that influence 
which positions individuals or groups will hold within the structure of a society (25-27). The 
term SEP encompasses other terms including social class and social or socioeconomic status 
(SES), despite these having different theoretical basis in epidemiology methods (28). Here, they 
will be used interchangeability, if originally reported as SES, that term will be used. There is an 
abundance of literature showing that better health is usually associated with social advantage 
compared to social disadvantage.  
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Regarding SEP patterns by race, it is important to understand the complex systemic 
effects of SEP. In general, compared to white women, black women are more likely to live in 
neighborhoods with higher poverty, more female-headed households, fewer college graduates, 
less purchasing power, face greater discrimination, multiple disease conditions, poorer health 
behaviors (e.g. poor sleep, smoking and substance use) lower income, home ownership, 
residential instability, overcrowding and unemployment (29-31).  
Black women with breast cancer, regardless of age, are more likely to be diagnosed at a 
more advanced stage of disease. Young black women are more likely to be diagnosed with 
regional or distant disease (32). Additionally, young black women are less likely to receive 
stage-appropriate treatment compared to young white women (32). 
Research on breast cancer incidence, SES, and race/ethnicity found that breast cancer 
incidence increased with increased SES in all racial/ethnic groups (33). Research has also shown 
that lower SES is associated with increased risk of more aggressive premenopausal breast cancer 
(20, 34). Results from SEER-NLMS show that among women diagnosed with breast cancer from 
1973 to 2001, lower income statistically significant increased the risk of distant stage disease 
(35).  
Age and SES are important for breast cancer outcomes research. Less is known about 
how lower SES trajectories over the lifecourse affect breast cancer outcomes. Breast cancer 
research suggests very strong influence of early childhood exposures on breast cancer risk affect 
onset later on in life; the interaction over time are complex and multifactorial. While the 
importance and need is evident, the research is scant. Anderson et al. examined the association of 
low SES with early menarche. Black women are nearly twice as likely to have early menarche 
compared to white women (36, 37). Epidemiological research has directly linked low SES during 
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childhood with earlier age at menarche (38). Lastly, when considering SES and risk of early 
menarche, it is important to consider environmental factors; specifically how environmental 
factors are patterned by SEP strata. These factors include prenatal exposure to cigarette smoke, 
childhood BMI changes and fluctuations, fruit and vegetable intake, built neighborhood 
environment (including access to parks) and chronic stress (39-42). 
Breast cancer studies need to better account for SEP since there is a large difference in 
SEP by race and by age, and since SEP is likely a strong contributor to the higher risk seen in 
young black women compared to white women (43). This is seen in 2013 where U.S. black 
households earned 59 cents for every white household earned dollar (44). Many cancer outcomes 
research use area-based SEP measures, but they have difficulty accounting for the variation at 
the household level. Even household or individual levels of SEP need to be interpreted as 
underestimated as they do not capture the racial differences in economic assets and wealth well 
documented in other fields of research; for example, in 2011 every dollar of wealth white 
households had, black households had only 6 cents (44). An issue emerges in modeling multiple 
factors of SEP in a single model due to high correlations between covariates. Another challenge 
of measuring SEP is that it is multidimensional, but often combined into a single variable for 
analysis use. An alternative is latent class models. The advantage of these models are: 1) they 
characterize SEP factors into meaningful classifications via the modeling, 2) can handle the 
clustering at the household, neighborhood level and with highly correlated factors. When this is 
used in tandem with tumor biology information, it can be a powerful tool to use in cancer 
disparities outcomes research (45).   
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Whereas to this point SEP has been reviewed as complex whole by race and age, the 
follow subsections further breakdown the individual factors that form composite SEP and 
evaluation the individual contribution to breast cancer risk.  
Education 
Regarding years of individual-level education, higher educational attainment is a 
statistically significant associated with greater risk of breast cancer incidence. However, when 
examining late-stage cancer diagnoses, women with a less than high school education are 1.8 
times (95% CI = 1.01, 3.12) as likely to diagnosed with a late-stage breast cancer compared with 
women with a college education or beyond (35).  
Income 
Regarding individual-level income, lower incomes are associated with late-stage breast 
cancer diagnosis. The odds of breast cancer diagnosis in women with family incomes less than 
$12,500, between $12,500 and $24,999 and between $35,000-$49,999 are 2.30 (95% CI = 1.31, 
4.05), 1.82 (95% CI = 1.07, 3.10) and 1.97 times (95% CI = 1.14, 3.41) as high than women who 
earn the highest income group of $50,000+ (35).  
Poverty 
Regarding individual-level poverty and late-stage breast cancer, breast cancer diagnosis 
in women who were at or below poverty status (ratio of family household income to poverty 
threshold less than or equal to 1) were 3.1 times (95% CI = 1.44, 6.76) as high as women who 
were over 600% poverty status. Furthermore, at every categorical level (100% to 200%, 200% to 
400%, and 400% to 600%) were statistically significant as increased odds of a late-stage 





SEP is reflected in screening patterns, where black women experience lower levels of 
mammographic screening and higher breast cancer specific mortality compared to white women 
(46). Access issues and neighborhood segregation create disparity, where black women are more 
likely to live in areas that are less likely to receive adequate and appropriate treatment compared 
to white women (47).  
1.2.2 Reproductive factors and breast cancer 
Reproductive factors for the risk of breast cancer have some of the highest and most 
consistent associations with breast cancer incidence (48). These well-known reproductive factors 
include age at menarche, parity, age at first and last full live birth, breastfeeding and oral 
contraceptive (OC) use. However, while these factors have been well established, less is known 
how these factors differ with respect to age among black women. 
Age at menarche and menopausal status 
The time period between the age at menarche and the age at natural menopause is called 
the total reproductive lifespan and is considered to influence breast cancer risk via hormonal 
pathways (onset and cessation of ovarian activity)(49). Patterns of breast cancer by total 
reproductive lifespan are complex when factoring risk factor exposure history by race. Generally, 
black women have earlier pubertal onset and menarche compared to white women of European 
descent (50, 51).  
Earlier age at menarche is associated with breast cancer. A review of 117 epidemiological 
studies found breast cancer incidence increased by a factor of 1.05 for every year younger at 
menarche (52, 53). Similarly and independently, the risk of breast cancer increases by a factor of 
1.02 for every year older at menopause (52). It is important to note that these meta-analyses were 
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stratified by other factors including childbearing, hormonal contraceptive use, ethnic origin, 
BMI, age, smoking and alcohol consumption, to ensure as much comparability between women 
with breast cancer and controls. When considering molecular subtypes, basal-like tumors are 
more strongly associated with increasing age at menarche compared to luminal A (54). Later age 
at menarche remains associated with lower risk of breast cancer when considering estrogen and 
progesterone hormone status, but some differences emerge. Earlier age at menarche is more 
consistently associated with ER+/PR- tumors compared to ER-/PR- tumors (55).  
However, less is known regarding age at menarche as breast cancer risk patterns in young 
black women. Harmonized data from the African American Breast Cancer Epidemiology and 
Risk (AMBER) Consortium found that later age at menarche was more strongly associated with 
a decreased risk of ER- tumors compared to ER+ tumors among black women (56). In a smaller 
sample size of black women with breast cancer, researchers found no associations between age at 
menarche and ER+/ER- breast cancer (57).  
Parity and breastfeeding 
Patterns by race regarding parity and breastfeeding are complex not completely 
understood. On average, U.S. black women, compared to white women, experience greater total 
pregnancies, earlier age of first pregnancy and breastfeed less and for shorter duration (58, 59). 
Further, research has found that black women typically have more children and at a younger age 
but also have lower prevalence of lactation (60-63). Regarding breastfeeding, rates are higher 
among mothers age 30 and older compared to younger mothers.  
 Breast cancer studies have established the association between parity and breast cancer 
(64). Research has found age to be critical in this association. It has been well established that 
increasing parity and early age at first full-term birth are associated with a decreased risk of 
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breast cancer, where women who have a first pregnancy before age 20 have around half the risk 
of breast cancer incidence vs. first pregnancy after age 30 (64, 65). Late age at first pregnancy 
among parous women increases breast cancer risk as well. Further, research as found that 
younger ages (and closer in birth timing) among parous women, particularly higher parous 
women, have an increased risk of breast cancer (66). Research has also found that age at each 
subsequent births have a decreased association on breast cancer incidence (48).  
When factoring in hormone receptor status, parity and age at first full-term birth is 
associated with reduced breast cancer risk among ER+/PR+ women, but does not affect risk of 
ER-/PR- breast cancer (67, 68). The protective effect of increasing parity on ER+/PR+ risk is 
observed in both women over and under age 40, but among ER-/PR- tumors increasing parity is 
associated with an increased risk (69). Nulliparity and delayed childbearing are more 
consistently associated with an increased risk for breast cancer among ER+ tumors compared to 
ER- tumors (70). The protective effect of decreased breast cancer risk by increasing parity has 
been shown to be limited to women who are older that age 40 (49, 71). However, studies that 
have included women under age 40 are limited. Thus, elucidating differences in breast cancer 
risk among young women in these factors is limited (69). 
Breastfeeding for over six months has a protective effect from breast cancer, particularly 
when the mothers are nonsmokers (72). Relatedly, research has found that high SES is associated 
with a greater likelihood of breastfeeding (73). Breastfeeding for an extended period, at least 
longer than one year, is associated with a decrease in breast cancer risk, including both HR+/HR- 
breast cancers (74). Generally, the positive associations between breast cancer and parity and late 
age at first full live pregnancy, late menopause in relation to breastfeeding have been studied 
among white women of European ancestry (75). Among black women, research has found 
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associations between parity, breastfeeding and breast cancer according to ER status. Thus, 
reproductive patterns relate to breast cancer subtype in important ways. 
Oral contraceptives and menopausal hormone therapy 
Oral contraceptives (OC) and menopausal hormone therapy (MRT) are estrogen and 
progesterone (or progestin) or with estrogen alone regimens. MHT is an effective treatment for 
the symptoms related to menopause (76). MHT regimens are usually estrogen and progestin (for 
women with an intact uterus). Progestin helps to protect the endometrium from hyperplasia 
caused by unopposed estrogen (77). Black women use OC less compared to white women (78). 
While less is known about the patterns of MRT, it has been shown that white women are more 
likely to be prescribed MRT than black women and that white women are more likely to adhere 
to MRT use than black women (79). 
The association of OC/MRT use and breast cancer is complex and displays some 
inconsistency. Women who use combined estrogen and progestin MHT for more than 5 years 
have an increased risk of breast cancer incidence (80). Conclusions from many observational 
studies in the early 2000’s were that estrogen alone and estrogen plus progestin both increased 
risk for breast cancer (81). However, results from the largest randomized clinical trial of 
hormone replacement therapy use breast cancer, the Women’s Health Initiative (WHI) differed. 
In the WHI trial, estrogen plus progestin (CEE 0.625 mg/d + MPA 2.5 mg/d) increased breast 
cancer incidence compared to no MRT (HR = 1.25; 95% CI: 1.07, 1.46) (and hindered breast 
cancer detection, leading to delay in diagnosis and thus, also increased mortality)(82). However, 
postmenopausal women with prior hysterectomy (and thus, no interference with breast cancer 
detection) who used estrogen alone (CEE 0.625 mg/d) had a decrease breast cancer incidence 
(HR = 0.77; 95% CI: 0.62, 0.95) (83). The WHI randomized clinical trial also reported no 
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statistically significant differences in hormone therapy and breast cancer association by BMI or 
by race when the trial stopped (82). Chlebowski and colleagues examined interactions of obesity 
and black race/ethnicity in two WHI randomized hormone therapy trials; they found estrogen 
plus progestin increased breast cancer incidence and estrogen alone decreased incidence, with no 
interactions by race/ethnicity or BMI (84).  
However, Hou and colleagues provide evidence that increased breast cancer risk from 
hormone therapy may not be the case for all postmenopausal women. Breast cancer risk can 
differ when stratified by BMI, race/ethnicity, and breast density (85). While other studies have 
also reported subgroup differences by BMI, race/ethnicity, and breast density (86), this is the 
largest study with 9,300 breast cancer cases. The Hou et al. study clarifies an increased risk of 
breast cancer from hormone replacement therapy use in women with a BMI under 25, while 
women with a BMI over 25, the most direct measure of risk would come from knowing breast 
density (87). Studies have shown that hormone replacement therapy initiation and use increases 
breast density (88), and discontinuation can decrease breast density (89).  
Positive association between hormone replacement therapy use and breast cancer risk, 
may vary by race/ethnicity related factors. Similarly, positive association between OC use and 
breast cancer risk, may vary by age and race/ethnicity related factors. In the WHI trial, increases 
in breast density from hormone replacement therapy did not differ by race/ethnicity. However, 
the Hou et al. study found HRT use was associated with greater than 20% increased breast 
cancer risk in white women but not black women (OR = 1.21; 95% CI: 1.14,1.28 vs. OR = 0.91; 
95% CI: 0.72, 1.14; P interaction = .04). Inconsistent results by randomized clinical trials and 




Althuis and colleagues assessed breast cancer risk factors for young women compared to 
older premenopausal women. They found that among women younger than age 35, young black 
women and recent OC use increased risk by 66% and 26% respectively (RR = 2.66: 95% CI: 1.4, 
4.9; RR = 2.26; 95% CI: 1.4, 3.6) (22). Additionally, these associations were observed to be 
strongest for ER- tumors. Data from the AMBER Consortium suggests that among black women, 
OC use within previous 5 years and recent use of long duration was associated with increased 
risk of ER+, ER- and triple negative (ER-/PR-/HER2-) breast cancers. The increased risk was 
apparent for 15 years of longer after stopping OC use. Additionally, association with OC use was 
more pronounced for overweight and obese black women (90). 
1.2.3 Family history 
Women with close relatives who have been diagnosed with breast cancer have an 
increased breast cancer risk; 2 times the risk if one first-degree female relative has been 
diagnosed and 5 times as high if two first-degree relatives have been diagnosed compared to 
average risk women. In certain cases, a family history of abnormal genes, such as BRCA1, 
BRCA2 and CHEK2, are associated with breast cancer risk. In family history, age is important 
when factoring breast cancer risk. Having family history of early-onset breast cancer is more 
greatly associated with risk of breast cancer among women who are less than 35 years in age 
(RR =3.22) compared to women who are 45-54 years old (RR = 1.51)(22). In a study among 
women diagnosed with breast cancer before age 30, BRCA1, BRCA2 and TP53 mutations were 
in nearly 50% of women who had family histories of breast cancer and in less than 10% of 
women with non-familial breast cancer (91). These mutations in women with breast cancer who 
are age 30 and younger show the cancer are strongly predicted by family history. While family 
history increased risk across all subtypes, the strength was highest for basal-like tumors (54). 
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1.2.4 Comorbid conditions and breast cancer by age and race 
Bodyweight before, during and after diagnosis  
 BMI is an important breast cancer risk factor that is differential by race and age. The 
general pattern of BMI in U.S. women is that black women have higher obesity prevalence 
compared to white women (92). National Health and Nutrition Examination Survey data from 
2013 to 2014, revealed that the obesity prevalence for white women was 38.2% and for black 
women was 57.2% (92). Temporal trends show that over a 12-year period from 1999 to 2010, 
white women showed no statistically significant increase in obesity. On the other hand, black 
women showed statistically significant estimated annual increase in odds of obesity prevalence 
during the same time period (93). Indeed, black women have over twice the odds of obesity 
compared to white women (OR = 2.10; 95% CI: 1.77, 2.50) (92).  
The association between BMI and breast cancer risk has been established. This 
association is differential by menopausal status (94). Most studies among 43 cohort studies, over 
100 case-control studies and 2 ecological studies that investigated increased BMI found a 
reduced breast cancer risk in premenopausal women and an increased risk in postmenopausal 
women (95). Among premenopausal women, overweight and obesity in childhood and 
adolescence are associated with reduced breast cancer risk, independent of BMI during 
adulthood (96). A prospective cohort study showered that greater BMI during younger ages is 
associated with decreased risk of breast cancer (97). Further study shows that premenopausal 
breast density may be important mediating factor in BMI (98). However, when factoring in high 
energy intake and lack of physical activity a positive associated with breast cancer risk has been 
shown (99). Regarding breast tumor subtypes, increasing BMI statistically significantly reduced 
the risk of luminal A tumors among premenopausal women (OR = 0.71; 95% CI: 0.57, 0.88), but 
it did not reduce breast cancer risk for basal-like breast tumors (54). 
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Among postmenopausal women, the associated increased breast cancer risk with 
increasing BMI is thought to be largely driven by increased in estrogen levels (100). Higher BMI 
equates to increased adipose tissue, a source of bioavailable estrogens (101, 102). The exposure 
time window to these estrogens may increase breast cancer risk (103). Several studies suggest 
that greater BMI is associated with greater insulin and insulin-like growth factors, which increase 
risk of breast cancer (104). Obesity has also been shown to have effects on inflammation, 
making its mechanisms complex and dynamic (105). 
Few studies have evaluated these associations in black women. In a recent review, only 8 
studies on body size and breast cancer among black women were identified. Here, the results 
were inconsistent with studies reporting inverse, positive and null associations while the obesity 
rates among black women are trending upward (106).  
Alcohol use 
Overall, black women consume less alcohol than white women and have different related 
risk factor patterns, such as reproductive factors or comorbid disease, that may influenced them 
to avoid alcohol (107-109). Indeed, a recent study revealed that 45% of the black women in the 
study population reported no alcohol consumption at all (110).  
Alcohol use is an established risk factor for breast cancer (111-113), shown to have a 
linear dose-response association (111, 114). Moderate alcohol consumption of one or two drinks 
per day has been associated with a 30 to 50% increase in breast cancer incidence (111). Previous 
research has found that this risk is confined to moderate consumption and does not vary with the 
timing of use, with heavier drinking patterns, or type of alcohol, but the increase in risk is greater 
in women with low BMI and with ER+ breast cancers (111). Additionally, alcohol use and 
longer duration of OC use have been shown to increase breast cancer risk as well, which may 
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have a common pathway (115). However, as the research on alcohol and breast cancer risk 
expands across the life course, the results are not consistent. 
New findings suggest that timing and patterns of alcohol exposure and type of alcohol are 
important in breast cancer risk (116).  Alcohol consumption in adolescent ages increases risk. 
Alcohol exposure between menarche before first pregnancy can increase incidence breast cancer 
risk (117). The critical period were breast tissue undergoes more rapid proliferation until first 
pregnancy is one vulnerable to breast cancer risk (118). These exposures in early adulthood have 
shown to be more important in cancer development than exposure later in life (118). In mouse 
models, alcohol exposure stimulates increases in ductal branching, epithelial proliferation and 
density, which can lead to greater risk of breast cancer (119). The type of alcoholic beverage 
may have differential influence on breast cancer risk. Although ethanol content are different 
according to different alcoholic beverages, most all epidemiologic studies report similar risk for 
all types of beverages (120, 121).  
Despite all the research on alcohol and breast cancer the underlying mechanisms are still 
unclear. Possible mechanisms include that alcohol being involved through increased levels of 
circulating sex hormones, enhancing breast epithelial cell responsiveness to them, producing 
genotoxic metabolite acetaldehyde and oxidative stress (116). Another possible mechanism 
through ER-dependent pathways, where transcriptional activity is greatly increased by alcohol 
intake and thus more strongly associated with hormone receptor positive breast tumors (116).  
Breast cancer subtype can confound the potential for differential risk by race, as it has 
been established that black women have more ER- and triple negative breast cancer and that 
alcohol use can change hormone metabolism. Recent research, using phases I and II of CBCS, 
found that black women consumed more than 7 drinks per week had significantly greater risk at 
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≤25 and >50 ages. It was also reported that among black women the positive association of 
drinking more than 7 alcoholic beverages per week with ER- and triple negative breast cancers 
were statistically significant (107). These associations were not significant for white women and 
no evidence of interaction between drinking alcoholic beverages and OC use or smoking were 
found. However, in subtype-stratified analyses, on more than 22,000 black women from the 
AMBER consortium found that black women who drink 7 or more alcoholic beverages per week 
had an increased risk across all subtypes (122). Here, heavier drinking black women saw an 
increased risk regardless of subtype. Similarly, there was no interaction by smoking status, OC 
use or menopausal status. Further study to determine which of factors apply most by race is 
needed to understand disparity of breast cancer incidence. 
Smoking 
 The epidemiological evidence on the association between cigarette smoking and breast 
cancer risk has been inconsistent. Recent literature supports a moderate association, particularly 
for women who smoke cigarettes for longer than 40 years, greater than 40 cigarettes per day and 
women who smoke for a long time prior to first pregnancy (123). These increases are 57%, 21% 
and 18%, respectively. Additionally, confounding by alcohol use is a concern in this association. 
In a meta-analysis of 15 cohort studies, current smokers and former smokers saw an estimated 
10% increased risk of breast cancer compared to never smokers (124). It was also found that 
women who initiated smoking before menarche and after menarche but 11 or more years before 
first birth had higher risk by 61% and 45%, respectively (124).  
The proposed mechanisms include cigarette smoke carcinogens, polycyclic aromatic 
hydrocarbons and nicotine-derived nitrosamines damaging DNA (125) and anti-estrogenic 
effects by cigarette smoke lowering circulating estrogen levels possibly creating a protective 
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effect (126). Additionally, p53, a frequently mutated gene in breast cancer, has been found in the 
breast tissue of smokers (127). Overall, the 2014 U.S. Surgeon General report on the health 
consequences of cigarette smoking concluded that there is insufficient evidence to identify a 
causal association between active smoking and breast cancer risk (128). 
 However, many of these studies have not considered breast cancer as a heterogeneous 
disease, which can mask associations between active cigarette smoking and distinct molecular 
subtypes. Findings from the WHI, suggested that smoking may be modestly associated with 
increased risk of ER+ breast cancer (129). Another study found a modest association between 
active smoking women aged 20 to 44 and ER+, but not triple negative, breast cancer (130). 
Less is known regarding the association of cigarette smoking and breast cancer by race. 
Rosenberg and colleagues assessed smoking and breast cancer and subgroups at higher risk 
among black women. They found a positive association with active smoking and increased risk 
for premenopausal breast cancer, particularly for ER+ cancer (131). Butler et al., using data from 
CBCS phases I and II, examined associations between cigarette smoking and risk etiologic types 
of breast cancer. Here, they found associations between smoking and increased Luminal breast 
cancer risk, but not Basal like, particularly among black women (132).  
Heart disease 
It is estimated that there are over 3 million breast cancer survivors in the U.S. and that 
nearly 90% of breast cancer patients survive at least 5 years after diagnosis (133). However, 
older women are more likely to die from other causes than breast cancer and cardiovascular 
disease (CVD) is the leading cause (134). Overall, CVD remains the leading cause of mortality 
in women (135). The prevalence of CVD in the U.S. is around 48 million compared to 3.3 
million for breast cancer and 1 in 3.3 deaths is attributed to CVD (135).  Black women have 
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higher rates of CVD than white women (135). CVD and breast cancer share common risk factors 
including diet, family history, obesity, physical activity, and alcohol, hormone replacement and 
tobacco use (136, 137). Lastly, CVD impacts breast cancer treatment options (138). Cancer 
therapies carry varying cardiotoxic effects, for example, the most commonly reported and 
monitored side effect of chemotherapy is left ventricular systolic dysfunction, a cardiovascular 
effect (139).  
Diabetes 
 It is estimated that 9.4% of the U.S. population have diabetes (140) and the prevalence is 
expected to continue to increase. Most diabetes (90%) is type 2 disease which is characterized by 
reduced insulin secretion and resistance with diagnosis in adulthood compared to type 1 which is 
insulin deficient. The prevalence is higher among blacks (12.7%) compared to whites (7.4%) and 
higher among adults with less than a high school education (12.6%) compared to more than a 
high school education (7.2%). Diabetes is associated with breast cancer (141, 142). Meta-
analyses found that women with diabetes have a 23% greater risk of breast cancer compared to 
women without diabetes and that preexisting diabetes is associated with a 37% and 17% greater 
all-cause and breast cancer specific mortality (143, 144), which persists after adjustment for 
stage of disease (145). It is estimated that approximately 16% of breast cancer patients have 
coexistence of diabetes (146). This coexistence can impact adjuvant treatment therapies and 
chemotherapy toxicity (147). Additionally, women with diabetes are associated with less 
screening mammography compared to cancer-free controls (148), which can lead to delays in 
diagnosis. Lastly, the anti-diabetic medication metformin may improve outcomes for diabetic 
breast cancer patients (149). Specifically, retrospective clinical data has shown higher rates of 
pathologic response after preoperative chemotherapy in patients with diabetes and breast cancer 
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who use metformin (150). However, more research is needed to determine if it has a positive 
benefit for non-diabetic breast cancer patients.   
1.2.5 Summary of social, behavioral and comorbid condition factors 
In summary, disparity between black and white women in breast cancer exists and in 
certain subgroups, such as young black women, the disparity is widening. Understanding breast 
cancer disparities is complex, in part due to the heterogeneity of the disease, and in part due to 
the variety of comorbid conditions, social, behavioral and access to care factors. These factor 
patterns are complex, dynamic, and interactive. Adding to the complexity is ability, or lack of 
ability, to change these patterns to reduce disparity. The patterns of familial breast cancer history 
for example are non-modifiable and differ by important subgroups, race and age. Harder to 
modify factors include SEP and reproductive factors. In general, the patterns are that black 
women, compared to white women, have earlier pregnancy, more children, shorter timing 
between births, breastfeed less, breastfeed for short duration, and have less socioeconomic 
position/social advantage. Generally, these patterns lead to poorer health and worse breast cancer 
outcomes. Lastly, among easier to modify factors like bodyweight, alcohol use and cigarette 
smoking, black women are on average more likely to be obese but use less alcohol. Moreover, 
many of these factors are not independent factors of one another as they relate to breast cancer. 
Further study is needed to understand how these patterns differ and relate to each other and how 
these patterns may impact subgroup’s breast cancer outcomes differently. 
1.3 Description of clinical characteristics of breast cancer by race and age 
In general, compared to white women, black women report greater advanced stage of 
disease and more aggressive disease in various studies. The following sections will elaborate on 
what is known about the patterns of breast cancer clinical characteristics by race and age.  
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1.3.1 Tumor characteristics 
Breast cancer is being seen less as one disease as information on tumor characteristics 
grows such as expression of ER, PR, human epidermal growth factor receptor 2 (HER2) and how 
it affects cancer incidence. There is also increasing information that the etiology of breast cancer 
may differ by expression status. Identification of intrinsic tumor subtypes via gene expression 
arrays and immunohistochemistry has greatly helped our understanding of heterogeneity, as well 
as subtype distribution patterning by age and race. Here, ER- and basal-like breast cancers are 
most common among black younger women (151).  
In addition to subtypes, categorization of breast cancer into at least two etiologic types 
have different patterns of risk factors associations. Risk factors and breast cancer incidence also 
differ by ER and PR status. Risk factors with significant heterogeneity by ER/PR include age, 
menopausal status, BMI, first pregnancy and MRT, but not for family history or alcohol use (70). 
Breast cancer risk factors may vary by molecular subtypes identified in expression studies, 
suggesting etiologic (in addition to clinical) heterogeneity of breast cancer (54). 
Breast cancer staging 
 Breast cancer stage is a pathologic measure of tumor size, lymph node status and tumor 
metastases. It ranges from 0 to 4; with 4 being the highest and is any cancer with metastases, 
regardless of size or lymph node status. Usually, the higher the stage is associated with worse 
prognosis.  
 The distributions of stage by race and age have been determined. Generally, black 
women have lower proportions of local disease distributions and higher proportions of later stage 
breast cancer compared to white women (152). Recent data from SEER 17 found the distribution 
of stage I breast cancer in black women is 35.4% compared 50.3% in white women and the stage 
IV distribution 8.1% in black women vs. 4.2% in white women (153). These distributions have 
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remained relatively stable over time (154). Regardless of age, the odds of late-stage breast cancer 
for black women is 2.2 times (95% CI = 1.22, 3.80) as high as white women (35). The 
distributions of stage by age have been determined. Likewise, younger women have lower 
proportions of local disease distributions compared older women (6). Less is known about stage-
specific incidence in young black vs. white women. Johnson et al. found an increase in distant 
disease, but also found it to be independent of race/ethnicity (155). Similarly, Anderson et al. 
found increasing rates of distant disease among both young black and white women during the 
time period from 1974 to 2003 (18). While this project is not focused on mortality from breast 
cancer, death rates due to breast cancer at three as high in black women under age 45 compared 
to young white women, thus, may reflect greater later stage diagnosis in young black women.  
 Here it is important to consider stage migration, where the changes in staging group can 
be attributed to improvements in diagnostic imaging technology or increasing use of imaging 
studies, over time, can classify breast cancer patients in a higher stage group. The effect can 
partly explain increase in distant disease (155). 
Hormone receptor status 
Breast cancer incidence also can vary by hormone receptor status. Data from SEER 17 
found the distribution of ER+/PR+ status among black women is 49.4% compared to 68.4% in 
white women and the distribution of ER-/PR- status among black women is 37.5% compared to 
18.6% in white women. Here, the diagnosis ER-/PR- breast cancer among black women is 2.4 
(95% CI: 2.3-2.5) times as high as ER-/PR- among white women (153). It has been established 
that black women compared to white women are more likely to be diagnosed with hormone 
receptor negative tumors, which are more aggressive than hormone receptor positive tumors, 
which can lead to poorer prognosis, even without regard to the stage of the disease(156). 
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When hormone receptor status is stratified by stage similar results emerge. Data from the 
Multiethnic Cohort Study found localized tumors with ER+/PR+ status the distribution among 
black women was 53.8% compared to 70.3% among white women. For localized tumors with 
ER-/PR+ status the distribution among black women was 7.1% compared to 2.3% among white 
women. For localized tumors with ER-/PR- status the distribution among black women was 
30.7% compared to 15.9% among white women. After stratification of stage, black women have 
higher proportion at localized stage (31% vs. 16%) and advanced stage (32% vs. 20%) (157). 
Lastly, a few studies have examined hormone receptor status by young U.S. black and 
white women. Here, overall ER+ status has increased among both black and white women under 
age 50, and ER- status has reduced or remained stable (158, 159).  
Tumor grade 
Grade denotes cells appearance and growth patterns and represents a score on a scale of 1 
to 3. Grade 1 is low grade or well differentiated and a better prognosis. Grade 2 is moderate 
grade and grade 3 is high grade or poorly differentiated and worse prognosis. Data from the 
Massachusetts Cancer Registry in women diagnosed during the years 1999 to 2004, the 
distribution of tumor grade 1 among white women is 20% compared to 13% among black 
women, the distribution of tumor grade 2 among white women is 42% compared to 33% among 
black women, the distribution of tumor grade 3 among white women is 29% compared to 48% 
among black women(160). Among young black and white women, both high and low grade 
increased, with no evidence that either was increasing at a faster rate (18).   
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Breast cancer subtype   
 
 Breast cancer, although often referred 
to as a single disease, is heterogeneous, 
distinguished by subtypes (histologic and 
molecular), which can be  
linked with distinct risk factors and 
biologically variable in presentation, 
treatment responsiveness and overall disease outcome. Gene expression profiling techniques 
allow for greater understanding of genetic variability. Routinely evaluated biological markers 
can serve as proxies for molecular subtypes as well, including the presence or absence of 
hormone receptors and overexpression of HER2 protein (5).  Five molecular subtypes (luminal 
A, luminal B, HER2 overexpression, basal and normal-like tumors) are identified by gene 
expression profiling techniques. Table 4 shows the breast cancer classification according to IHC 
cellular markers or IHC and mircoarray expression methods (gene signatures).  
Incidence rates by breast cancer subtype differ between black and white women. Overall, 
luminal A (HR+/HER2-) is most common among both white and black women(5). Luminal A 
breast cancers are associated with higher survival. Incidence of basal subtype (HR-/HER2-) is 
twice as high in black women compared to white women (24 per 100,000 vs. 12 per 100,000)(5).  
Breast cancer incidence being higher among black women under 40 years old compared 
to white women under 40 years old is not observed when breast cancer molecular subtype 
information (HR-/HER2+, HR+/HER2+, HR+/HER2-, triple negative) is separated. Only when 
subtype information is not present or when all breast cancer subtypes are combined, is the 




Luminal A ER+ and/or PR+, HER2− 
Luminal B ER+ and/or PR+, HER2+ 
Basal-like ER−, PR−, HER2−,  
HER2+  ER-, PR-, HER2+ 




ages including premenopausal, have higher rates of triple-negative breast cancer but lower rates 
of HR+/HER2- breast cancer after the age of 35 years(161). The higher occurrence of 
premenopausal basal-like breast cancer among black women was also shown in the CBCS, 
which may contribute to the poor prognosis of young black women breast cancer experience 
(162). They found a higher prevalence of basal-like breast cancer in younger black women, but 
concluded that basal-like breast tumors do not seem to be inherently more aggressive in black 
women compared to white women. The racial disparity in breast cancer-specific mortality may 
be due to treatment and access differences for Luminal A and other subtypes, in addition to the 
higher basal-like prevalence seen in young black women (163). 
1.3.2 Summary of breast cancer clinical characteristics by race 
Compared with white women, black women are younger at diagnosis, more likely to be 
diagnosed at later stage, have larger tumor size, higher tumor grade and more aggressive 
subtype. Younger-onset breast cancer is more aggressive compared to older women (6). Young 
women have greater prevalence of basal-like, higher-grade tumors, ER- tumors, HER2 
overexpression, p53 mutations and greater metastases compared to older women (6-8, 10). 
Certain risk factors impact breast cancer incidence equally across all subtypes. These include 
family history, OC use, HRT use, alcohol use and cigarette smoking. Other risk factors appear to 
impact breast cancer incidence differentially. These include reproductive and body size, where 
basal-like breast cancers are associated with younger menarche age, younger age at first birth, no 
breastfeeding and higher parity (55, 164).  
1.4 Breast cancer treatment delay 
Treatment delay can be defined at the time to surgery or the time to chemotherapy.   
There is no standard time set, as studies categorize and define this time in various ways. 
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Additionally, breast cancer survival is often the outcome of interest in these studies. For 
example, studies have found that delaying surgery by 30 days and chemotherapy by 90 days can 
lead to poorer survival (165, 166). However, the timeliness of breast cancer treatment can 
contribute to disparity between black and white women and younger and older women (167).  
Reasons for treatment delay have been explained in different ways, including 
racial/ethnic differences in knowledge, religious beliefs, social support, access to care, financial 
factors, medical care communication and system-level factors (168).  Indeed, timeliness of breast 
cancer treatment is complex, with interaction of clinical and SEP factors. Prior research has 
shown that delay contributes to later stage diagnosis which leads to greater mortality and is 
differential by race/ethnicity (169). Among younger women 39 years or younger, treatment delay 
was statistically significantly different between black and white women, women with public or 
no insurance compared to private insurance, and women of low socioeconomic status compared 
to high socioeconomic status (170). Determinants of treatment delay and racial disparity was 
examined in CBSC. Here, McGee et al. found that determinants of treatment delay did vary by 
race and disparity by race in treatment delay was found in women younger than age 50 (167).  
The relationship between tumor characteristics and treatment delay is a complex 
interaction, where treatment delay can affect tumor characteristics, tumor characteristics can 
affect treatment delay and SES factors can affect both. For example, tumor staging and hormone 
receptor status are considered tumor characteristics, which influence treatment delay, but they 
also are factors influenced by personal factor profiles at the time when they are diagnosed. 
However, this delay may be partially attributed to a more favorable breast cancer and/or SEP in 
order to get second medical opinions. Generally, ER+ tumors are smaller and less treatment 
delay is observed, whereas ER- tumors are larger and greater treatment delay is seen. Regarding 
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race, black women experience greater treatment delay than white women (167). It is important to 
understand these interactions. Thus, the goal in this aim is to better understand how we code and 
use these factors beyond just race and age, and both models are expanding the understanding of 
how we incorporate these factors into models of associations between social and behavioral 
factors/tumor characteristics and treatment delay. Tumor characteristics influence on treatment 
delay is complex, where factors that are tumor characteristics are also influenced by personal 
factors, such as size, stage, and hormone receptor status.  
1.5 Rationale and motivation for this study 
This project provides an overview of the complex and dynamic ways that race, age and 
socioeconomic position combine and interact to create multifaceted patterns across the 
lifecourse. This study ultimately affects our understanding and treatment of breast cancer for 
younger women and black women compared to older women and white women, with an 
emphasis on understanding how these patterns are related to access to care. This work began by 
first examining differential distributions of SES and comorbidity factors among women in North 
Carolina and compare those distributions to the underlying population. Despite all efforts to 
reduce cancer disparities, certain subgroups, such as young black women, continue to experience 
adversity. Thus, detailed attention to the complexity of these factors is greatly needed.  
In addition to SES and comorbidity factor patterns, understanding disparity in breast 
cancer outcomes is complex, in part due to the heterogeneity of the disease. Breast cancer is seen 
less as one disease as at least four different subtypes of breast cancer have been identified. Thus, 
improving our understanding of how race and age relate to SES and comorbidity factor patterns 
and tumor characteristics is critical to interpreting breast cancer outcomes. This study helps 
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clarify how these patterns relate to race and age. Beyond race and age, we also the relationship of 
SES and access factors with treatment delay. 
This study employed novel methodological approaches in its use of LCA, particularly for 
SES. Due to high correlations, multiple indicators of SES cannot be simultaneously used in 
models. Combining SES into a single continuous measure for analysis was considered. However, 
it is difficult to interpret due to the measure being unit-less. Thus, this project used LCA to better 
characterize SES factors and tumor characteristics, to assign meaningful classifications, and to 
allow for greater interpretation of relevant groups of indictors of SES factors and tumor 
characteristics. LCA was used to create latent classes that more easily described SES factor 
patterns and tumor characteristics. The strength of LCA is by identifying latent groups, which 
describe variability among multiple, correlated and observed variables. After identifying classes 
of SES, comorbidities and tumor characteristics, this project examined how these classes impact 
treatment for breast cancer.  
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CHAPTER 2: SPECIFIC AIMS 
Black women have higher breast cancer incidence before the age of 50, more severe 
disease and higher mortality compared to white women. Young-onset breast cancers tend to be 
more aggressive and have distinct risk factor and tumor biology profiles compared to later-onset 
breast cancer. Research has focused on both biological and non-biological factors associated 
with differential outcomes. Despite efforts, breast cancer outcomes continue to be worse in 
certain subgroups, particularly among young women and black women.  
Understanding disparity in breast cancer mortality is complex, in part due to the 
heterogeneity of the disease, and in part due to the variety of health care access patterns. A wide 
range of socioeconomic, behavioral, access factors and tumor characteristics affect outcomes. 
This project: 1) examined the ways that socioeconomic position, access to care and tumor 
characteristics combine to create multifaceted patterns that differ by race and age and 2) 
examined how those patterns relate to treatment delay, one contributor to outcome disparities.  
Aim 1: To develop an integrated understanding of access to care and tumor 
characteristics in Carolina Breast Cancer Study Phase 3 (CBCS3) and the state of North 
Carolina.  
Aim 1A: To examine the distributions of socioeconomic status (SES), comorbidity, 
access to medical care factors according to race and age. Hypothesis: Race and age are complex 
demographic variables that segregate with a wide range of SES, comorbidity, and access to care 
variables. Approach: Using data from CBCS3 and North Carolina’s Behavioral Risk Factor 
Surveillance System (BRFSS), we estimated weighted frequencies for a variety of SES and 
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comorbidity factors, comparing black vs. white and younger (≤50 years) vs. older (>50 years) 
women. These factors included marital status, family history of breast cancer, insurance, income, 
education, BMI, rurality, diabetes, heart disease, cigarette smoking, job loss, and financial and 
transportation issues.  
Aim 1B: To examine the distributions of individual tumor characteristics according to 
race and age. Hypothesis: More aggressive individual tumor characteristics will be associated 
with higher risk among black women and younger women. Approach: Logistic regression was 
used to estimate odd ratios and 95% confidence intervals as a measure of the association between 
individual tumor characteristics and younger black women, older black women and younger 
white women compared to older white women in the CBCS3. These individual tumor 
characteristics included tumor size, nodal status, grade, and hormone receptor status.  
Aim 1C: To identify SES, comorbidity, access to care and individual tumor 
characteristics patterns (latent classes) that are prevalent among women in CBCS3 and describe 
these patterns by race and age. Hypothesis: Patterns of SES, comorbidity and access to care 
factors and tumor characteristics will be associated with race and age Approach: Latent class 
analysis was used to identify SES, behavioral, access to care and individual tumor characteristics 
patterns. Logistic regression and polytomous logistic regression estimated odd ratios and 95% 
confidence intervals as a measure of association in the relationships between SES, access to care, 
and tumor characteristics latent classes and race/age. 
Aim 2: To estimate the association between SES, access to care patterns, tumor 
factors and treatment delay by race and age. Hypothesis: Patterns of SES, comorbidity and 
access to care factors and tumor characteristics will be associated with specific tumor 
characteristics and treatment delay by race and age. Approach: Generalized linear models were 
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used to estimate relative frequency differences (RFDs) and 95% confidence intervals (95% CIs) 
as measures of association between 1) delay in treatment initiation greater than 60 days and 2) 
treatment duration measured in quartiles, and race, age and latent class patterns of individual-
level SES, access to care, and tumor characteristics. Generalized linear models stratified by race 
were adjusted by age and models stratified by age were adjusted by race. 
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CHAPTER 3: RESEARCH STRATEGY 
3.1 Study design overview 
The proposed study involves two primary aims and a comprehensive analytic 
methodology to thoroughly describe social determinants, comorbid conditions, access to care, 
and clinical characteristics by subpopulations of race and age and examine patterns of SES and 
access to care factors association with breast cancer treatment initiation and duration.  
A conceptual model of our aims is presented in Figure 4. In the statistical analysis 
section, difference sections of this conceptual diagram will be shaded in blue to articulate the 
analytical approach by aim. Aim 1A will use descriptive statistics to assess the distributions of 
socioeconomic position, comorbidity and access factors among black and white and young and 
older women with breast cancer in CBCS3. Aim 1 will also compare the distributions of SES and 
comorbidities by race and age among women with breast cancer in CBCS3 to that of women in 
the North Carolina Behavioral Risk Factor Surveillance Systems dataset. Aim 1B will examine 
the distributions of individual tumor characteristics by race and age. Aim 1C will use latent class 
analysis (LCA) to identify groups of women according to patterns of social and comorbid 
factors. LCA is a data reduction tool that identifies unobservable, or latent, subgroups within a 
population (171). Lastly, Aim 3 will investigate how these patterns of SES, comorbidity, access 




Figure 3.1. Summary of aims 
 
3.2 Study populations 
3.2.1 Carolina Breast Cancer Study 
The Carolina Breast Cancer Study Phase III (CBCS3) is the third phase of a population-
based case-control study design that combines epidemiology and molecular biology to examine 
environmental and genetic risk factors for breast cancer in North Carolina. CBCS3 is case-only. 
All breast cancer cases are identified within 2 months by rapid case ascertainment, implemented 
by the Lineberger Comprehensive Cancer Center (LCCC) and the North Carolina Central Cancer 
Registry (NCCCR). To be eligible for inclusion, participants must have been female, between the 
ages of 20 and 74 (at the time of diagnosis), received a first and primary diagnosis of breast 
cancer between May 1, 2008 and October 31, 2013 and must have resided in the 44-county study 
region. In total, 2,998 women were enrolled in CBCS III. To investigate potential differences in 
risk factors by age and race, CBCS employed a randomized recruitment strategy that was 
designed to oversample young (≤ 50 years) and black women such that half the population was 
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invite the patient to the study. Study participants consented to a nurse-administered in-person 
interview that took place in the study participant’s home or another pre-arranged location. The 
in-person interview included a questionnaire that included items on family and personal medical 
history, reproductive history, smoking, alcohol, diet, medication use and occupational history. A 
blood sample and anthropometric measurements of height, weight, and hip circumference were 
also taken. The average time between study enrollment and interview was 6 months. Patients 
who declined participation were not substantially different from those who participated based on 
demographic characteristics of age and race.  
At the time of interview, study participants were asked permission to obtain formalin- 
fixed, paraffin-embedded (FPPE) tumor blocks or tissue slides from the hospital where the 
diagnostic surgery was to be performed. Pathology reports and medical records from the treating 
facilities of the participants were also obtained. Clinical and pathological data abstracted from 
medical records and pathology reports included tumor size, stage, and node status. For all cases, 
a single pathologist determined tumor grade. Permission to use the data was obtained from the 
CBCS Steering Committee. This study was approved by the University of North Carolina at 
Chapel Hill IRB and informed consent was obtained from each participant of the parent study. 
3.2.2 BRFSS 
The Behavioral Risk Factor Surveillance System (BRFSS) is a state-based random 
telephone survey with a cross-sectional study design. It was established in 1984 by the Centers 
for Disease Control and Prevention. The purpose is to collect uniform, state-specific information 
on risk and preventive health behaviors that are associated with chronic diseases, injuries and 
preventable infectious diseases that affect noninstitutionalized US adult population. The BRFSS 
is designed to provide state-specific estimates. Each state health department is responsible to 
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conduct its own data collection, thus the BRFSS is decentralized, unlike other federal health 
surveys (172, 173). The North Carolina Division of Public Health conducts monthly BRFSS 
interviews and data are analyzed annually (174).  
To be comparable to the CBCS3 study population, we restricted the 2010 BRFSS 
population to women who self-identified as either black or non-Hispanic white and were 
between the ages of 20 and 74 years old. We utilized 2010 data, a midpoint time relative to 
CBCS3 study period. BRFSS data are weighted for the probability of telephone number 
selection, the number of adults in a household, and the number of phones in a household and are 
adjusted to reflect the demographic distribution of North Carolina's adult (age 18 and older) 
population. The North Carolina BRFSS analytical set was publicly available and a Data Use 
Agreement was signed.   
3.3 Data processing 
The CBCS data files are maintained by a single statistician. All survey information is item-
coded, double-key entered and error checked. The CBCS conducts quality checks to ensure 
accuracy of data. Once data is obtained all variable coding will be reviewed in relation to 
analysis to be conducted in this study. 
Because of the decentralized structure of the BRFSS, each state collects and submits data to 
the CDC every month. At the monthly submission routine data processing and cumulative data 
quality tasks are performed. Any problems are resolved between a CDC and state programmer. 
Annually, steps to prepare the next data collection for the next year’s survey include developing 
edit specifications, programming the editing software, and producing state requested telephone 
sample estimates. To reduce interviewer, data entry, and skip errors, CDC staff employs skip 
patterns, together with some consistency edits. A Windows-based editing program performs data 
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validations and helps users with output lists of errors or warnings that may exist in the dataset. 
Year-end processes are run for the entire year data for each state, which include additional, 
limited data cleanup and state-specific fixes. Then data are assigned weights and adding 
calculated variables.  
3.4 Latent class analysis 
In model-based clustering, despite many variables at the users deposal, considering all of 
them can be unnecessary, even detrimental. In order to avoid unnecessary model complexity, 
over parameterization and high dimensionality, we employed variable selection in model-based 
clustering before estimating the model. The goal of performing variable selection for clustering 
is to retain only the relevant variables (175). Here, relevance is defined in terms of probabilistic 
dependence (176). Relevant variables have essential clustering information and their distribution 
directly depends on the group membership variable, unlike irrelevant variables, which may be 
redundant (include similar information to relevant information) or uninformative (provides no 
discriminative information)(175). Model-based clustering and variable selection strategies are 
based on distributional assumptions on relevant and irrelevant variables. Here, we will be using 
the local independence assumption, where the relevant variables are conditionally independent 
within the groups. This is the standard assumption of the latent class analysis model. 
Additionally, we will consider the global independence assumption. Taken together, these 
proposed methods for variable selection in latent class analysis should lead to improved 
classification and more accurate selection of the number of classes (177).  
To identify groups based on categorical factors, we will use latent class analysis (LCA) 
approach, a statistical technique for analysis of multivariate categorical data (178). LCA 
identifies unobservable, or latent, subgroups within a population (171). The model then 
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probabilistically groups each observation into a latent class, a variable indicating underlying 
subgroups of individuals based on observed characteristics. Membership in the subgroup is said 
to be “latent” because membership in a class cannot be directly observed. Lastly, latent classes 
are mutually exclusive and exhaustive. LCA will allow for better understanding of the impact 
patterns of multiple factors to target subgroups interpretation of breast cancer outcomes studies. 
3.5 Statistical analysis  
3.5.1 Aim 1: To develop an integrated understanding of access to care and tumor 
characteristics in Carolina Breast Cancer Study Phase 3 and the state of North Carolina. 
Aim 1 is subdivided into Aim 1A, 1B and 1C. 
Aim 1A: To examine the distributions of SES, comorbidity, access to medical care 
factors according to race and age.  
Using data from CBCS3 and North Carolina’s Behavioral Risk Factor Surveillance 
System (BRFSS), estimate weighted frequencies for a variety of SES and comorbidity factors, 
comparing black vs. white and younger (≤50 years) vs. older (>50 years) women. These factors 
are highlighted in orange in the conceptual diagram for Aim 1A. These factors include marital 
status, insurance, income, education, rurality, diabetes, heart disease, obesity, and cigarette 
smoking. 
Aim 1B: To examine the distributions of individual tumor characteristics according to race 
and age.  
Logistic regression models were used to estimate odd ratios (ORs) and 95% confidence 
intervals (95% CIs) as a measure of the association between individual tumor characteristics and 
race and age. Weighted percentages were also calculated. For race and age cross-classification, 
younger black women, older black women and younger white women were compared to older 
white women. Individual tumor characteristics included tumor size, nodal status, grade, and 
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hormone receptor status. Tumor size (≤ 2cm vs. >2cm), nodal status (positive vs. negative) and 
histologic grade (I and II vs. III) were obtained from medical records abstraction. Estrogen 
receptor (ER) status, progesterone receptor (PR) status, human epidermal growth factor receptor 
2 (HER2), and Triple Negative (TN) status (positive vs. negative) were obtained from pathology 
reports abstraction. Analyses were done in SAS version 9.4 (SAS Institute, Cary, NC). Graphs 
were created in GraphPad Prism version 8.1.1 (GraphPad Software, San Diego, CA).  
Aim 1C: To identify SES, comorbidity, access and tumor characteristics patterns and 
describe patterns by race and age.  
LCA was used to identify groups of individuals based on numerical factors using PROC 
LCA a SAS package (179), which is freely available. An iterative approach to parameter 
estimation using expectation-maximization (EM) for maximum-likelihood (ML) estimation 
generated estimates of all model parameters and item-response probabilities of class assignment. 
Currently, there is no universal consensus on the modeling process to select the optimal or 
minimal set of latent classes in LCA. Thus, we used several criteria to determine the number of 
classes from the ML solution using many sets of starting values. We examined the G2 likelihood 
ratio test statistic produced using 100,000 sets of starting values, Akaike’s information criterion 
(AIC) and Bayesian Information Criterion (BIC), a goodness-of-fit measure to find more 
parsimonious models, where a smaller AIC and BIC suggest a better model fit. Additionally, we 
evaluated entropy, where higher values reflect better classification. We then expanded model 
specification for multiple-groups LCA to examine differences in exposure factor patterns by race 
and age. Here, we tested for measurement invariance across groups for differences between 
younger and older and black and white women. We compared a series of latent class models to 
determine the optimal model for parsimony and model fit using these criteria described above. 
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Analyses were done in SAS version 9.4 (SAS Institute, Cary, NC). Graphs were created in 
GraphPad Prism version 8.1.1 (GraphPad Software, San Diego, CA). 
3.5.2 Aim 2: To estimate the association between SES, access to care patterns, and tumor 
factors and treatment delay by race and age. 
Association between latent classes and treatment initiation and duration by race and age 
Descriptive analyses for treatment initiation and treatment delay were stratified by race 
and age. Generalized linear models were used to estimate relative frequency differences (RFDs) 
and 95% confidence intervals (95% CIs) as measures of association between 1) delay in 
treatment initiation greater than 60 days and 2) treatment duration measured in quartiles, and 
race, age and latent class patterns of SES, access to care, and tumor characteristics. Generalized 
linear models stratified by race were adjusted by age and models stratified by age will be 
adjusted by race.  
Association between latent classes and treatment duration by treatment modality 
Generalized linear models were used to estimate RFDs and 95% CIs as measures of 
association between treatment duration and race, age and latent class patterns of SES and access 
to care by treatment modalities.  
Association between single factors and treatment duration by treatment modality 
Generalized linear models were used to estimate RFDs and 95% CIs as measures of 
association between treatment duration and race, age and unadjusted single factors, both overall 
and by treatment modalities. All analyses were done in SAS version 9.4 (SAS Institute, Cary, 




3.6 Strengths and limitations 
 Previous studies of social, comorbidities, and access to care factors and tumor biology for 
breast cancer in disparate subpopulations are limited due to: 1.) Focus on either the social factors 
or tumor biology, few sources are equipped to examine both, 2.) Small sample sizes of young 
women and black women and 3.) Lack breast cancer subtype information. This study has several 
strengths that overcame these challenges. CBCS oversamples young black women and 
statistically provided adequate numbers for subgroup analysis. Additionally, CBCS has quality 
detailed information regarding both social factors and tumor characteristics.  
 Another strength of CBCS data is individual-level SES information. A limitation of 
previous studies of large populations is use of area-level SES information. Area-level data, such 
as census tracts or zip codes, are used as a proxy for individual SES but may be more difficult to 
use when there is distinct heterogeneity within an area of analysis (167). Additionally, using 
area-level SES as proxies may overestimate individual-level SES, as area-level SES has been 
shown to have an independent association with breast cancer (180).  
 Although this study has several strengths, it is important to recognize its limitations. 
CBSC3 study design did not include recruitment for a control group. Thus, our case-case 
prevalence odd ratios use subset cases as the referent group and cannot estimate risk relative to 
controls. To address comparability with the population of NC as a whole, we compared the 
distributions of the cases to the cross-sectional study design of BRFSS, which represented the 
underlying population, at the midpoint during the time period which CBCS3 participants were 
enrolled, 2010.  
 Ultimately, this study has great potential to help narrow the gap of breast cancer mortality 
disparity by race and age. Specifically, this study provided a detailed understanding of: 1.) How 
social, comorbidities, access to care and tumor factor patterns affect each race and age groups 
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differentially and 2.) Subpopulation patterns of tumor characteristics and how these patterns may 
impact treatment for breast cancer. The findings of this study can help future cancer outcomes 
and intervention studies. The clusters of social and access factors by race, age and tumor biology 
can be of meaningful clinical relevance to help target and guide prevention and interventions in 
high-risk subpopulations.     
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CHAPTER 4: DEVELOPING AN INTERGRATED UNDERSTANDING OF ACCESS TO 
CARE AND TUMOR CHARACTERISTICS PATTERNS BY RACE AND AGE  
4.1 Introduction 
 U.S. population-based breast cancer mortality rates are 42% higher for black women 
compared to white women and the mortality disparity is present at all ages and diagnostic stages 
(5, 181). Since the early 1980s, this mortality gap has increased, partly reflecting 
disproportionate increases in survival among white women (5). When considering age, younger 
black women (age 35 or less) have greater than three times the mortality compared to white 
women of the same age (22, 23). Understanding breast cancer disparities by race and age is 
complex, due to the biological heterogeneity of the disease, presence of comorbid conditions, 
and the multifaceted interaction of social, behavioral, and access to care and care quality factors 
(4, 20). Disentangling the biological and access factors that drive breast cancer mortality is 
critical to developing effective interventions.  
 To address the knowledge gap of how race, age, social determinants, comorbid 
conditions and tumor characteristics interact, we used data from 2,998 women with invasive 
breast cancer in the population-based Carolina Breast Cancer Study Phase 3 (CBCS3) (2008-
2013), which oversampled younger (<50 age at diagnosis) women and black women. We used 
latent class analysis (LCA), a person-oriented approach to reduce highly dimensional data and 
capturing complex patterns that vary between people (34, 48, 69, 182). We also compared 
biology and access characteristics to the underlying population of North Carolina, using 
Behavioral Risk Factor Surveillance Study (BRFSS) data.  North Carolina is a socio-
geographically and ethnically diverse state with wide ranging rural areas as well as focal urban 
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areas and corresponding differences in access to care, income and education. The resulting data 
identify key person-centered groupings of patients and important multivariable contributors to 
breast cancer mortality. 
4.2 Methods 
4.2.1 Data sources and study populations 
 CBCS3 is a population-based case-only study that was initiated to comprehensively 
evaluate the survivorship following invasive breast cancer diagnosis. All cases were identified 
within two months of diagnosis by rapid case ascertainment via the UNC Rapid Case 
Ascertainment Core in conjunction with North Carolina Central Cancer Registry. Younger (<50 
years in age) and black cases were oversampled by randomized recruitment so that half of the 
population was younger and half was black. All procedures performed in CBCS3 were in 
accordance with the ethical standards of the Institutional Review Board of the University of 
North Carolina at Chapel Hill. Informed consent was obtained from all participants. Eligibility 
criteria defined participants as female, between the ages of 20 and 74 at the time of diagnosis, 
and receiving a first, primary diagnosis of breast cancer between May 1, 2008 and October 21, 
2013 with residence in the 44-county study area.  
 For comparisons of CBCS3 to the general North Carolina population, we examined the 
2010 Behavioral Risk Factor Surveillance System (BRFSS), a state-based random telephone 
survey with a cross-sectional study design. To be eligible for inclusion, participants were age 18 
and older, resided in households within any North Carolina county. BRFSS interviews are 
conducted monthly and data are collected and analyzed annually, and we utilized 2010 data, a 
midpoint time relative to CBCS3 study period. BRFSS data are weighted for the probability of 
telephone number selection, the number of adults in a household, and the number of phones in a 
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household and are adjusted to reflect the demographic distribution of North Carolina's adult (age 
18 and older) population. To be comparable to the CBCS3 study population, we restricted the 
BRFSS population to women who self-identified as either black or non-Hispanic white and were 
between the ages of 20 and 74 years in age.  The lead author (MAE) created and signed a Data 
Use Agreement for NC BRFSS for the analysis of publicly available NC BRFSS data. Sampling 
weights were applied to both data sources to match distributions in the original source 
population; in CBCS3 the source population was the 44-county study area and for NC BRFSS it 
was the state population. All presented SES and comorbid factors were assessed in both CBCS3 
and NC BRFSS. The categorization of these variables differed between datasets, however, we 
harmonized the CBCS3 and BRFSS to have exact levels for each categorical variable.  
4.2.2 SES and comorbidities factors: CBCS3 and NC BRFSS 
 For CBCS3, all SES and comorbidity information was assessed by a baseline 
questionnaire and nurse-administered questionnaire on family history and body mass index 
(BMI) measurement within, on average, 5 months of diagnosis. For 2010 NC BRFSS, all SES 
and comorbid information was assessed via a landline telephone survey. SES variables of interest 
included self-reported race (white vs. black), age (age at diagnosis in CBCS3; age at interview in 
BRFSS) (<50 years of age vs. ≥50 years of age), marital status (married vs. not married), income 
(USD > $50K, $15K to $50K and < $15K), education (college degree or higher, some college, 
technical or business school, high school graduate/GED and 0-12 years, no but high school 
degree), current health insurance (yes vs. no) and rural address (yes vs. no).   
 Education, income and marital status had comparable categories between CBCS3 and 
BRFSS and were harmonized by categorization. For health insurance, CBCS3 participants were 
asked at baseline if they currently had health insurance coverage and the type of insurance 
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(private health insurance purchased on their own or by husband or partner, private health 
insurance from their employer or workplace or that of their husband or partner, Medicaid, 
Medicare or other insurance that covered part of their medical bills) In BRFSS, participants were 
asked, “Do you have any kind of health care coverage, including health insurance, prepaid plans 
as HMOs, or government plans such a Medicare”. A “yes” response was coded as current health 
care coverage. The variable on current health insurance was dichotomous: “yes vs. no”. For 
rurality, CBCS3 participants were asked about their community type since age 25. We then 
collapsed the categorization to include city (large city [population >100K], suburb, and town or 
city with a population of <10k, 10-50K and 50-100K) vs. rural (rural, non-farm, in the country 
and on a farm). In BRFSS, rural status was assessed based on metropolitan statistical areas 
(MSA), which are defined by the US Office of Management and Budget as a metropolitan area 
distinct form another metropolitan area. MSA codes included: in the center city of an MSA, 
outside the center city of an MSA but inside the county containing the center city, inside a 
suburban county of the MSA and not in an MSA. Rural status included the category of “not in an 
MSA” while all other category we coded as “non-rural”. The final rural variable was coded as 
“yes vs. no”. 
 Comorbidity factors included diabetes (yes vs. no), heart disease (yes vs. no), smoking 
status (not current vs. current), and body mass index (BMI; <25 kg/m2, 25-30 kg/m2 and 30 
kg/m2). In CBCS3, diabetes and heart disease were determined by medical record abstraction as 
a comorbidity to breast cancer and were dichotomized as “yes vs. no”. In BRFSS, participants 
were asked, “have you ever been told by a doctor that you have diabetes?” If “Yes” and the 
respondent was female, the participant was asked, “Was this only when you were pregnant?” An 
affirmative response was coded as pre-diabetes or borderline is answered yes, which as less that 
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1% frequency. Participants were also asked if they had ever been told they had angina or 
coronary heart disease, an affirmative response was coded as “yes”. For smoking, CBCS3 
participants were asked about their current tobacco smoking status via questionnaire. Current 
smokers included participants who had: 1) smoked at least 100 cigarettes in their lifetime and 
reported smoking at the time of the interview, or 2) quit at diagnosis and within 1 year prior to 
diagnosis. Non-current smokers included former smokers (smoked at least 100 cigarettes in 
lifetime and who quit at least 1 year prior to diagnosis) and never smokers. In BRFSS, a 
computed smoking status was used to assess current smoking status, originally with 4 levels: 
everyday smoker, someday smoker, former and non-smoker, recoded to “current (everyday and 
someday) vs. not current (former and non-smoker)”. For anthropometry, CBCS3 BMI was based 
on nurse measured anthropometric data and was measured in weight in kilograms/height in 
meters squared. In BRFSS, BMI was calculated and categorized as: neither overweight nor 
obese, overweight and obese. The variable was derived from self-report height and weight. The 
final variable for BMI was: less than or equal to 25, 25 to 30, and greater than 30.  
4.2.3 Access to medical care factors: CBCS3 
 Access to medical care factors included currently insured (yes vs. no), insurance type, 
rural residence, (yes vs. no), financial issues (yes vs. no), transportation issues (yes vs. no), job 
loss (yes vs. no) and North Carolina AHEC (Area Health Education Centers) region.  
Participants were asked about insurance, insurance type, rural status, job loss and AHEC region 
at baseline. Private insurance was defined as private health insurance from employer or 
workplace or that of the participant’s husband or partner. Other types included Medicaid, 
Medicare, other and none. For job loss, participants were asked if they had lost their job to 
diagnosis of breast cancer.  Participants were also asked at approximately 18 months follow-up 
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telephone survey from baseline if they could not see a doctor because of financial and 
transportation issues.  
4.2.4 Tumor characteristics: CBCS3 
 Tumor size (≤ 2cm vs. >2cm), nodal status (positive vs. negative) and histologic grade (I 
and II vs. III) were obtained from medical records abstraction. Estrogen receptor (ER) status, 
progesterone receptor (PR) status, human epidermal growth factor receptor 2 (HER2), and Triple 
Negative (TN) status (positive vs. negative) were obtained from pathology reports abstraction for 
98% of cases in CBCS3. IHC staining was done for the remaining 2% of cases without medical 
record data (183). HER2 was derived from Immunohistochemcial (IHC) and/or FISH assay. A 
positive ER or PR was defined as >10% cut point. Borderline cases were included with negative 
status. 
4.2.5 Statistical analysis  
 Weighted percentages were calculated for selected participants’ SES and comorbidity 
factors by race and age in CBCS3 and NC BRFSS. We examined SES, comorbidities, access to 
medical care and the individual tumor characteristic factors using latent class analysis (LCA) to 
identity groups of individuals based on numerical factors using PROC LCA a SAS package 
(179). LCA identifies unobservable, or latent, subgroups within a population that are mutually 
exclusive and exhaustive (171). The model probabilistically groups each observation into a latent 
class, a variable indicating underlying subgroups of individuals based on observed 
characteristics. An iterative approach to parameter estimation using expectation-maximization 
(EM) for maximum-likelihood (ML) estimation generated estimates of all model parameters and 
item-response probabilities of class assignment. We used several criteria to determine the 
number of classes from the ML solution using many sets of starting values. We examined the G2 
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likelihood ratio test statistic produced using 100,000 sets of starting values, Akaike’s information 
criterion (AIC) and Bayesian Information Criterion (BIC), a goodness-of-fit measure to find 
more parsimonious models, where a smaller AIC and BIC suggest a better model fit. 
Additionally, we evaluated entropy, where higher values reflect better classification. We then 
expanded model specification for multiple-groups LCA to examine differences in factor patterns 
by race and age. Here, we tested for measurement invariance across groups for differences 
between younger and older and black and white women. We compared a series of latent class 
models to determine the optimal model for parsimony and model fit using the criteria described 
above.  
 We examined the distribution of latent class categories stratified by race and age. We 
used logistic regressions and polytomous logistic regressions to estimate odd ratios (ORs) and 
95% confidence intervals (CIs) as the measure of association between SES, access to care 
patterns, individual tumor factors latent classes and race/age. All statistical analyses were 
conducted with SAS statistical package version 9.3 (SAS Institute, Inc., Cary, NC). P-values 
were for a two-sided test with an alpha of 0.05 for statistical significance.  
4.3 Results 
4.3.1 CBCS3 in context of the state of North Carolina 
 The CBCS3 was designed to assess race and age differences in breast cancer outcomes, 
and therefore oversampled black and younger women. However, our findings show that after 
weighting for randomized recruitment, CBCS3 shows generally similar distributions of 
socioeconomic and comorbidity variables as the BRFSS data for the state as a whole (Figure 
4.1). Racial and age-specific patterns for marital status, diabetes, heart disease, smoking status 
and income were very similar in both datasets. In both populations all socioeconomic and 
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comorbidity factors had greater than 10% prevalence, except heart disease shown in Tables 4.2 
and 4.3. Compared to white women, black women were less likely to be married, more 
commonly resided in non-rural areas, were more likely to be obese, had lower income and had 
lower proportions of health insurance and education. Compared to older women, younger women 
were more likely to earn higher levels of income and have higher level of education. Some 
expected differences were observed for rurality, given that the CBCS3 sampled only from the 
most populous 44-counties in the state. The CBCS3 population also had a slightly greater 
proportion of women with current health insurance and post high school education. White 
women in CBCS3 were more somewhat more likely to be in the highest category of income 
compared to white women in BRFSS.  
Compared to white women in CBCS3, black women in CBCS had lower proportions of 
private health insurance and rural residence, but higher proportions of Medicare and both 
financial and transportation barriers to care (Table 4.4). Compared to older white women, 
younger white women and both younger and older black women in CBCS had higher proportions 
of Medicaid, job loss due to breast cancer diagnosis, and financial and transportation barriers to 
care.  
  Barriers to cancer care and clinical characteristics of tumors are not included in BRFSS, 
but we assessed distributions of these variables in CBCS3. Table 4.4 shows individual barriers to 
care by race and age and Table 4.5 shows clinical characteristics. Black younger women had 
more financial and transportation issues and experienced more job loss due to breast cancer 
diagnosis. Overall, older white women had the most favorable tumor characteristics, with more 
aggressive features seen for both younger and black women (Figure 4.4).   
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4.3.2 Latent classes and patterns by race and age 
 Given the multiplicity of variables that comprise socioeconomic status, barriers to care, 
and tumor biology, respectively, and the tendency for characteristics to aggregate within 
individuals, we sought to develop latent classes for these variables. We a priori identified three 
separate latent class domains: 1) SES factors, 2) barrier to care factors and 3) tumor 
characteristics. For the SES factors, a model with two latent classes had lowest AIC, BIC and 
likelihood-ratio G2 statistic compared to one, three, four, five or six-class models. For the 
barriers to care, two classes were optimal, and for tumor characteristics, four latent classes had 
the lowest AIC, BIC and likelihood-ratio G2 statistic. We examined contingency tables (Tables 
4.6 - 4.8) of the latent class posterior probabilities. We observed no correlation among the latent 
class groups and no further collapsibility, suggesting that these three latent classes were a stable 
classification solution. 
 Social, comorbidity, access to care and tumor factors determined distinct class 
membership. Figure 4.2 shows the relative frequency of each latent class and the posterior 
probabilities that members of each latent class endorsed each factor category in the models for: 
SES factors (panel A), barriers to care (panel B) and tumor characteristics (panel C). For the two-
class model measuring SES factors, 54% were in the High SES/Low Comorbidity latent class, 
which was characterized by a high probability of the highest categories of income, education and 
being married and low probability of comorbidities. For the two-class model for barriers to care, 
87% of women were in the Less Barriers latent class, with lower probability of being uninsured, 
having financial or transportation issues, residing in rural areas, or job loss. For the four-class 
model measuring tumor characteristics, 40% of the women were in the HR+/HER2-/Node 
Negative latent class, which was characterized as HR+, HER2-, smaller tumor size, node 
negative and lower grade tumors. The HER2+/Higher Grade class (10%) was characterized by 
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highest probabilities of having HER2+ breast cancers and higher probabilities of higher grade, 
node positive and larger tumor size. The HR+/HER2-/Larger Tumor/Node Positive class (29%) 
was characterized by highest probabilities of having HR+, larger tumor size and node positive 
tumors. Lastly, the TNBC/Higher Grade class (21%) was characterized by highest probabilities 
of TNBC and higher grade tumors.  
 Race and age were associated with latent class membership for all three domains we 
evaluated. As shown in Figure 4.3, when controlling for the effect of age, black race was 
positively associated with low SES (OR = 6.3, 95% CI: 5.2, 7.8; vs. high SES), more barriers to 
medical care (OR = 5.6, 95% CI: 3.9, 8.1; vs. less barriers) and more aggressive aggregated 
tumor characteristics (e.g., TNBC OR = 3.8, 95% CI: 3.0, 4.8) compared to white women. 
Controlling for race, younger age was negatively associated with low SES (OR = 0.5, 95% CI: 
.41, .61; vs. high SES), but positively associated with more barriers to medical care (OR = 2.1, 
95% CI: 1.6, 2.9; vs. less barriers) and more aggressive aggregated tumor characteristics (e.g., 
TNBC OR = 2.3, 95% CI: 1.8, 2.9).  Further cross-classification on race and age also showed 
these patterns. 
 Cross-classifying on race and age, both race and age were strong determinants of class 
membership patterns. As shown in Table 4.1, low SES was less common in younger white 
women compared to older white women, but was substantially more common in black women of 
all ages. Compared to older white women, higher frequency of barriers to care was observed in 
younger white women, younger black women older black women, (OR of 3.3, 7.8 and 15.3, 
respectively, for high vs. low barriers). In the tumor characteristics model, older white women 
had the lowest frequency of HER2+/Higher Grade class membership (vs. HR+/HER2-/Node 
Negative) with younger white, older black and younger black women, having higher frequency 
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of these larger, node positive tumors (OR of 2.6, 2.0 and 6.3, respectively). Similar low 
frequency of HR+/HER2-/Larger Tumor/Node Positive disease was observed in older white 
women. Lastly, the relative probability TNBC/Higher was higher among younger white, older 
black and younger black women (OR of 2.0, 3.4, and 9.0) respectively.  Taken together, these 
models suggest a compounding of high risk SES, access, and tumor biological factors for 
younger and black women. 
4.4 Discussion 
 The CBCS population-based cohort of women with breast cancer, which oversampled 
younger and black women, has helped further elucidate the complexity of race and age 
disparities. Women in CBCS3 were representative of women as a whole in North Carolina, with 
women in CBCS3 and BRFSS showing similar distributions of SES and comorbidity factors. 
Slightly higher income, education and non-rural residence in CBCS3 compared to BRFSS as a 
whole likely reflects CBCS3’s sampling of more populous counties. It may also reflect 
differences in participation demand for the two studies, with CBCS3 requiring a home visit, an 
extensive follow up schedule and BRFSS including just a single telephone interview. Many 
individual variables differed by race and age in the CBCS and to evaluate person-centered 
patterns, we used latent class analysis to show that black women were much more likely to have 
low SES, more aggressive aggregated tumor characteristics, and experience more barriers to 
medical care. Compared to older women, younger women were more likely to have higher SES, 
but had more aggressive aggregated tumor characteristics and experienced more barriers to 
medical care. Constructing and examining these covariates in aggregate helps to summarize a 
deeper understanding and a more nuanced view of race and age in breast cancer disparities.  
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 Based on previous literature racial differences observed in CBCS3 portend important 
differences in mortality. Racial differences in diagnosis, treatment and mortality have been 
shown to be greater among women who are unmarried (184), live in more rural areas (185), have 
lower SES (186-189), and have more comorbid conditions (190). Our observation of higher 
obesity rates in CBCS3 patients compared to the NC BRFSS population may be explained by 
obesity’s status as a risk factor for cancer (16, 92, 191). An additional consideration is the 
difference in the measurement of height and weight in both studies. A nurse in CBCS3 
objectively measured height and weight, whereas in BRFSS these measures were self-reported, 
which tends to result in underreporting of obesity (192, 193). Social, economic and cultural 
barriers to care, including insurance and cancer-care cost, have also been shown to contribute to 
racial disparities (194-196). Our results are consistent with the well established literature on 
racial differences in tumor biology. Black women are at much greater risk of higher-grade, ER 
negative and triple-negative breast cancers (197-199), even after controlling for age and stage. 
Younger and black women are more likely to have subtypes of breast cancer tumors that are 
more aggressive, treatment resistant and without clear molecular targets for treatment (156). Yet, 
little is known about the cancer experience of younger black women and thus, the disparity is 
widening (4).  
 Breast cancer mortality is higher in poorer communities regardless of race/ethnicity 
(200). Numerous analyses of racial identity and socioeconomic and social environment factors 
have made it evident that race is a sociopolitical construct in additional to a biological or genetic 
characteristic (43).  Socioeconomic disadvantages are more prevalent in Black communities 
compared to white communities, including insurance, income, education, economic, 
environmental and structural factors (29). Prevalence estimates for modifiable factors, such as 
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cigarette smoking and obesity, are higher with less education and below poverty level among 
women (200), in part, because targeted cigarette company advertisements (201), environmental 
changes and decreases in physical activity (202).  
 Previous population-based breast cancer studies have used area-level SES composite 
scores (e.g., area-level education or income and/or individual insurance) (196, 203, 204), but 
such approaches have varying validity by dataset because SES manifests in different ways in 
distinct populations (205). Area-level SES has been used as a continuous index of social and 
economic indicators, but it is difficult to interpret because it lack an identifiable unit and the 
assumption of a constant linear relationship may not be valid. Additionally, SES measured at the 
area-level does not fully capture individual variation, which is needed to inform intervention 
approaches. Palumbo et al. using, latent class models, identified factors of advantage and 
disadvantage neighborhood SES and measured the association of neighborhood SES, race and 
breast cancer tumor characteristics. Consistent with our findings, they found that high 
disadvantage neighborhood SES (i.e., higher proportions of neighborhoods with single with 
dependents, below poverty line, low vehicle access, black race) was associated with more 
aggressive tumor characteristics (i.e., lower proportions of Luminal A breast cancers, earlier 
stage, smaller size and lower grade) (45). Importantly, this study also found lack of concordance 
when comparing the latent class variables with a continuous neighborhood SES index, 
suggesting that SES characteristics are better represented by multiple latent classes than by a 
single index. Indicators of SES are not perfectly correlated, which makes LCA an advantageous 
alterative measurement tool in assessing multidimensional SES factors in cancer outcomes 
research. Strong links between SES, tumor characteristics, and access patterns suggest that 
analyses that integrate biological and access characteristics are important for understanding 
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mortality disparities. The current analysis extends previous studies that integrated race, SES, and 
individual tumor characteristics by also incorporating reported barriers to care, tumor 
characteristics patterns, individual level SES, and by examining these differences by race, with 
race as a covariate not and as a characteristic of the latent class models, and by race and age 
simultaneously. 
 Our study should be interpreted with some limitations in mind. First, we were unable to 
restrict our BRFSS analysis to the same sampling region used for CBCS3 so some comparisons 
may reflect regional differences in the state rather than differences between the study population 
and the source population. Second, it is possible that we are underestimating some access and 
biological disparities relative to the most underserved patients in the state. Notably, over 90% of 
CBCS3 women has some health insurance, higher than reported rates nationally and in NC 
during this time period. However, we did include many uninsured patients and because our goal 
was to identify patterns in overall SES and comorbidity factors, and we do not expect that the 
latent classes would be substantially different when expanding to the entirety of NC. Third, we 
also considered only a limited number of potential domains that could be associated with 
mortality disparities, however we were able to decrease dimensionality of these domains 
considerably. Our study has several key strengths including the population-based study design of 
CBCS3, which oversampled young and black women with breast cancer. Another strength is 
depth of data on socioeconomic, demographic, access and biology.  Finally, our population size 
was substantial enough to be able to find stable latent classes. 
4.5 Conclusion   
 Overall, previous studies have shown that breast cancer mortality is a complex 
combination of race, SES, and genetic factors. This paper is a step towards more fully capturing 
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and comprehensively examining the interaction and patterning of all these important indictors 
that reflect health disparity. 
Probabilistic model-based clustering methods identified unique patterns based on SES, 
barriers to care, and biological factors. Together, these factors can help specify interventions to 
reduce breast cancer mortality disparities. Future research should evaluate how these factors 






Figure 4.1. Distributions of categorical demographic and comorbid characteristics for women in 
the Carolina Breast Cancer Study 3 (2008-2013) and Behavioral Risk Factor Surveillance 






Figure 4.2. Probabilities of responses to items for A) two-class model measuring SES, B) two-
class model measuring access to medical care C) four-class model measuring tumor 


































































































































Figure 4.3. Odds ratios and 95% confidence intervals for covariates (race and age) of latent classes, Carolina Breast Cancer Study 3 
(2008-2013) 
  





























Table 4.1. Distribution and odds ratios with 95% confidence intervals of latent classes, Carolina Breast Cancer Study 3 (2008-2013) 
by age and race 
  
 

















No. (%) No. (%) No. (%)   No. (%)  No. (%) 
SES/Comorbidity latent classes 
    
  
 
     
Low SES/High comorbidity 1428 (47.6) 134 (9.4) 259 (18.1) 
 
455 (31.9)  580 (40.6) 
High SES/Low comorbidity 1570 (52.4) 617 (39.3) 493 (31.4) 
 
286 (18.2) 174 (11.1) 
Low vs. high, OR (95% CI)   0.5 (0.4-0.6) 1.0 ref  3.2 (2.5-4.1) 6.2 (4.7-8.1) 
Access to care latent classes            
Less barriers to care 2514 (84.1) 709 (28.2) 737 (29.3)  482 (19.2) 574 (22.8) 
More barriers to care 476 (15.9) 42 (8.8) 15 (3.2)  258 (54.2) 180 (37.8) 
Less vs. more, OR (95% CI)   3.3 (1.6-6.4) 1.0 ref  15.3 (7.8-29.9) 7.8 (4.1-15.4) 
Tumor Characteristics latent classesa            
HR+/HER2-/Node Negative 1091 (36.5) 290 (26.6) 419 (38.4)  117 (10.7) 265 (24.3) 
HER2+/Higher Grade 335 (11.2) 86 (25.7) 59 (17.6)  99 (29.5) 91 (27.2) 
HR+/HER2-/Larger Tumor/Node 
Positive 
944 (31.6) 259 (27.4) 181 (19.2) 
 
301 (31.9) 203 (21.5) 
TNBC/Higher Grade 617 (20.7) 115 (18.6) 90 (14.6)  222 (36.0) 190 (30.8) 
HER2+ vs. smaller, OR (95% CI)   2.6 (1.9-3.6) 1.0 ref  6.3 (4.3-9.1) 2.0 (1.4-2.8) 
HR+ vs. smaller, OR (95% CI)   2.3 (1.5-3.6) 1.0 ref  6.3 (3.9-10.0) 2.6 (2.5-3.8) 
TNBC vs. smaller, OR (95% CI)   2.0 (1.5-2.9) 1.0 ref  9.0 (6.1-13.0) 3.4 (2.5-4.6) 









Race and age, y 
  
 





























Married 63.4  76.0 67.6  43.1 39.8 
Income ($USD)        
>50K 52.5  67.4 56.7  33.5 24.4 
>15-50K 35.3  26.9 34.2  44.2 47.6 
≤15K 12.2  5.7 9.2  22.3 28.1 
Education        
Some college, 
technical school, 
college or higher 
71.1  84.6 69.4  70.3 58.2 
HS graduate/GED 21.8  12.6 24.1  22.8 26.1 
0-12 years, but no HS 
degree 
7.1  2.8 6.5  6.9 15.6 
Current Health insurance 95.8  94.9 97.6  91.2 92.3 
Rural address 19.1  19.1 21.3  8.5 16.4 
Comorbid factors        
Diabetes 13.8  2.8 13.8  8.8 33.2 
Heart Disease 6.6  0.9 8.8  2.3 8.6 
Current smoking status 16.0  19.6 12.9  22.6 19.2 
BMI (kg/m2)        
≤25 27.5  40.9 28.0  17.0 11.6 
25-30 30.6  27.6 34.5  24.2 23.8 
>30 41.9  31.5 37.5  58.8 64.6 
Abbreviations: BMI, body mass index; HS, high school; GED, general education development 
a All variables had <1% missing (married n=1; education n=1; current health insurance n=2; rural 
address n=1; diabetes n=0; heart disease n=0; current smoking status n=1; BMI n=12) except 
income which was missing n=24, 56, 26, 53 for younger black, older black, younger white, and 
older white women, respectively. 






Table 4.3. Select SES and comorbid factors, women in the Behavioral Risk Factor Surveillance 
System (2010), by age and race 
 
  Race and age, y 
  
 












% (SE)  % (SE) % (SE)  % (SE) % (SE) 
Socioeconomic position 







Married 65.3 0.95  73.8 1.60 70.4 1.07  41.4 3.19 40.0 2.93 
Income ($USD) 
  
          
>50K 47.9 1.06  59.3 1.78 46.9 1.36  29.7 3.03 25.2 2.66 
>15-50K 41.5 1.04  34.7 1.74 43.9 1.33  51.9 3.31 48.3 3.16 
≤15K 10.6 0.61  6.0 0.78 9.2 0.79  18.4 2.32 26.5 2.81 
Education 
  
          
Some college, technical 




74.3 1.50 59.9 1.21 
 
65.8 2.98 44.0 2.65 
HS graduate/GED 26.9 0.87  21.0 1.40 30.8 1.15  28.6 2.86 37.4 2.80 
0-12 years, but no HS 
degree 7.6 0.50 
 
4.7 0.74 9.3 0.75 
 
5.6 1.41 18.6 2.31 
Current health insurance 84.5 0.79  83.0 1.34 91.2 0.78  74.6 2.92 79.9 2.45 
Rural address 32.3 0.81  33.2 1.41 32.7 0.97  28.8 2.35 32.2 2.12 
Comorbid factors 
  
          
Diabetes 11.7 0.58  5.8 0.76 14.4 0.85  10.5 1.79 31.3 2.81 
Heart Disease 3.6 0.30  1.3 0.31 6.0 0.56  2.3 0.74 7.6 1.72 
Current Smoking status 18.3 0.77  21.0 1.41 15.6 0.97  16.4 2.08 19.1 2.29 
BMI (kg/m2) 
  
          
≤25 37.7 0.99  44.6 1.76 39.1 1.24  26.1 2.96 16.7 2.05 
25-30 31.7 0.99  31.8 1.76 33.8 1.21  25.7 3.04 32.5 2.85 
>30 30.5 0.93  23.6 1.44 27.0 1.12  48.2 3.35 50.8 2.96 
Abbreviations: HS; high school; BMI, body mass index; GED, general education development 
All variables had <1% missing (married n=12; education n=2; current health insurance n=6; rural 
address n=0; diabetes n=2; heart disease n=36; current smoking status n=19; BMI n=12) except 
income which was missing n=39, 96, 160, 505 and BMI which was missing n=37, 31, 88, 183 







Table 4.4. Distribution of barriers to medical care of women in the Carolina Breast Cancer Study 
3 (2008-2013) by age and race 
  
 
 White  Black   
Barriers to carea 
All cases 
(n=2,998) 






















Current health insurance 95.8  94.9 97.6  91.2 92.3 <.05 
Insurance type         
Private 57.6  84.7 51.7  57.7 41.0  
Medicaid 7.3  6.8 3.5  26.9 12.1  
Medicare 23.3  2.4 31.3  4.6 33.7  
Other 7.4  0.9 11.2  1.9 5.6  
Uninsured 4.3  5.2 2.4  8.9 7.7  
Finance barrier to care 12.2  14.0 7.9  28.7 18.0 <.001 
Transportation barrier to 
care 
5.6  3.9 3.1  15.8 12.7 <.001 
Rural address 19.1  19.1 21.3  8.5 16.4 <.001  
Job loss as a result of 
cancer 
3.1  3.9 2.3  6.1 3.6 <.001 
a All variables had <1% missing (current health insurance n=5; insurance type n=2; rural address n=13; 
job loss n=25) except finance barrier and transportation barrier which were missing n=39 and n=40 for 
older white, n=50 and n=55 for younger white, n=64 and n=68 for older black and n=82 and n=83 for 
younger black women, respectively. 
b Weighted percentages account for the different sampling probabilities for NC population estimates  








Table 4.5. Distribution and odds ratios and 95% confidence intervals of tumor characteristics, Carolina Breast Cancer Study 3 (2008-
2013), by age and race 
  
 
















% SE % SE (95% CI) % SE (95% CI)   % SE (95% CI) % SE (95% CI) 
Tumor size, cma 
    
  
 
    
≤2 58.7 1.10 66.0 1.76 52.2 1.83 
 
52.9 1.85 35.8 1.79 
>2 41.3 1.10 34.0 1.76 47.8 1.83 
 







22  20  
OR of  >2 vs. ≤2  
  
1.0 ref 1.8 (1.4-2.2) 
 
1.7 (1.4-2.1) 3.5 (2.8-4.3) 
Nodal statusa 
   
      
Negative 65.3 1.06 70.5 1.67 59.2 1.8 
 
61.8 1.78 51.0 1.85 
Positive 34.7 1.06 29.5 1.67 40.8 1.8 
 







10  10  
OR of Positive vs. Negative 
  
1.0 ref 1.6 (1.3-2.0) 
 
1.5 (1.2-1.8) 2.3 (1.9-2.8) 
Histologic gradea 
    
  
 
    
I and II 64.6 1.04 73.1 1.64 58.8 1.81 
 
52.0 1.84 43.9 1.84 
III 35.4 1.04 26.9 1.64 41.2 1.81 
 







19  15  
OR of III vs. I & II 
  
1.0 ref 1.9 (1.5-2.4) 
 
2.5 (2.0-3.1) 3.5 (2.8-4.3) 
HR negative statusb 21.1 0.88 16.3 1.37 20.8 1.49 
 







16  18  
OR of Negative vs. Positive 
  
1.0 ref 1.3 (1.0-1.8) 
 
2.3 (1.8-3.0) 3.0 (2.3-3.8) 
PR negative statusb 31.2 1.03 26.7 1.64 28.0 1.65 
 







18  21  
OR of Negative vs. Positive 
  
1.0 ref 1.1 (0.8-1.3) 
 
2.2 (1.8-2.8) 2.4 (1.9-3.0) 
HER2 positive statusb 15.6 0.82 14.2 1.29 17.3 1.39 
 































% SE % SE (95% CI) % SE (95% CI)   % SE (95% CI) % SE (95% CI) 
OR of Positive vs. Negative 1.0 ref 1.3 (1.0-1.7) 1.2 (0.9-1.6) 1.4 (1.0-1.8) 
TN positive statusb 15.3 0.76 11.4 1.18 14.8 1.30  23.8 1.57 28.2 1.67 
Missing 64  24  7   16  17  
OR of TN vs. non-TN   1.0 ref 1.3 (1.0-1.8)  2.4 (1.8-3.2) 3.0 (2.3-4.0) 
Abbreviations: OR, odds ratio; CI, confidence interval; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor 





Figure 4.4. Odds ratios and 95% confidence intervals of individual tumor characteristics among 
younger black women, older black women and younger white women compared to older white 
women in the Carolina Breast Cancer Study 3 (2008-2013), N = 2,998 
  









































































































Table 4.6. Access to care by SES/comorbidity latent classes (n=2997) 
SES/Comorbidity latent classes 
High Low 
Access to Care latent classes No. (%) No. (%) 
Less Barriers 1541 (55.8) 1220 (44.2) 
More Barriers 26 (11.0) 210 (89.0) 
 
Table 4.7. Tumor characteristics by SES latent classes (n=2987) 
SES/Comorbidity latent classes 
High Low 
Tumor Characteristics latent classes No. (%) No. (%) 
HER2+/ Smaller Tumor 448 (50.0) 448 (50.0) 
HER2+/ Higher Grade 169 (51.2) 161 (48.8) 
Larger Tumor/ Node Positive 293 (47.6) 322 (52.4) 
TNBC/ Higher Grade 656 (57.2) 490 (42.8) 
 
Table 4.8. Tumor characteristics by access to care latent classes (n=2986) 
Access to Care latent classes 
Less Barriers More Barriers 
Tumor Characteristics latent classes No. (%) No. (%) 
HR+/HER2-/Node-  1085 (39.4) 61 (26.0) 
HER2+/ Higher Grade  304 (11.1) 26 (11.1) 
HR+/HER2-/Larger Tumor/ Node+ 799 (29.0) 96 (40.9) 





Table 4.9. Select reproductive exposure history of women in the Carolina Breast Cancer Study 3 
(2008-2013) by age and race 
  
 
 White  Black  
























Age at menarche (y)        
<11 8.5  8.3 6.4  10.1 12.6 
11-12 43.0  41.9 45.3  43.1 44.1 
≥13 48.5  49.8 48.3  46.8 43.3 
Parity        
Nulliparous 15.2  14.2 19.7  11.0 16.9 
1-2 births 55.7  56.1 61.1  48.4 51.0 
3+ births 29.2  29.7 19.2  40.6 32.1 
Age at 1st full-term pregnancy 
(y)c 
       
<26 63.9  66.4 39.8  81.3 74.2 
≥26 36.1  33.6 60.2  18.7 25.8 
Oral contraceptive use        
Never 21.5  22.9 13.1  30.4 19.1 
Current 5.2  1.5 17.0  0.7 8.5 
Former 73.2  75.6 69.9  69.0 72.3 
Oral contraceptive use duration 
(y) 
       
Never 21.5  22.9 13.1  30.4 19.1 
<5 30.9  32.4 23.9  33.1 35.4 
5-10 26.2  26.1 28.4  22.9 26.9 
>10 21.3  18.6 34.6  13.6 18.6 
Breastfeedingc        
Never 55.6  57.0 41.0  70.0 58.8 
Ever 44.4  43.0 59.0  30.0 41.2 
Breastfeeding duration        
Never 55.7  57.0 41.0  70.0 58.8 
≤0-3 months 14.1  13.2 16.2  12.5 18.1 
>4 months 30.2  29.8 42.7  17.4 23.1 
Menopausal estrogen therapyd        
Never 57.1  53.1 N/A  72.8 N/A 
Current 13.4  15.6 N/A  4.6 N/A 
Past user 29.5  31.3 N/A  22.6 N/A 
a All variables had <1% missing (age at menarche n=5; parity n=0; age at first full-term pregnancy n=4; oral 
contraceptive use n=24; oral contraceptive use duration=24; breastfeeding among parous n=0; breastfeeding 
duration n=1) except menopausal estrogen therapy which was missing n=15 and 42 for older black and older white 
women, respectively. 
b Weighted percentages account for the different sampling probabilities for NC population estimates  
c dominator is among parous women 




CHAPTER 5: PATTERNS OF SOCIOECONOMIC STATUS, ACCESS TO CARE AND 
TUMOR CHARACTERISTICS AND DELAYS IN BREAST CANCER TREATMENT 
BY RACE AND AGE  
5.1 Introduction  
 Black women have a 42% higher breast cancer mortality rate than white women, and 
black women under the age of 45 have a breast cancer mortality rate more than twice as high as 
white women of the same ages (5, 43). These mortality differences, overall and at younger ages, 
have been attributed to a variety of factors including screening guidelines and screening use, 
later stage at diagnosis, more adverse tumor biology, social determinates of health factors and 
access to early detection and treatment factors (23, 196, 199, 206, 207). Post-diagnosis factors, 
such as timely initiation of treatment, improve survival; yet this relationship is complex 
interaction of clinical and socioeconomic status (SES) factors (169). Moreover, breast cancers 
diagnosed in black women are more likely to have aggressive tumor characteristics and poorer 
tumor characteristics are also associated with lower SES. This leads to delay in cancer treatment 
being more frequent in black women compared with white women, perpetuating the disparities 
racial mortality (206, 208). A better understanding of SES, barriers to accessing care, and tumor 
characteristics and identifying modifiable intervenable factors may help inform intervention 
strategies for black and younger women diagnosed with breast cancer. 
 Previous research on white-black differences in treatment delay has been limited because 
many used area-level SES proxy variables or are single intuition based and many focused on 
delay in treatment initiation. Our objective was to assess latent classes of SES and access to care 
and delays in treatment initiation and duration. Here, we examined detailed individual-level data 
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on SES and barriers to care, and were able to consider treatment initiation and treatment 
completion of the entire treatment plan, using detailed complete prospective information on 
surgeries, radiation therapy, and chemotherapy modalities Using resources form the Carolina 
Breast Cancer Study Phrase 3 (CBCS3), a population-based study initiated to disentangle tumor 
biological factors and the role of health services in breast cancer disparities, we identified 
distinct SES, barriers to care and tumor factor patterns. We estimated the associations of SES, 
barriers to care and tumor factor patterns on treatment initiation and duration by race and age. 
Then, we estimated associations of race, age, SES and barriers to care patterns among patients in 
the highest quartile of treatment duration by treatment modality. Lastly, recognizing the potential 
drivers of prolonged treatment duration, we examined modifiable individual factors for 
associations with treatment duration by treatment modality. 
5.2 Methods 
5.2.1 Data source and study population 
 CBCS3 is a population-based cohort study of women diagnosed with invasive breast 
cancer. All cases were identified within two months of diagnosis by rapid case ascertainment via 
the North Carolina Central Cancer Registry. Younger (<50 years in age) and black cases were 
oversampled by randomized recruitment so that half of the population was younger and half was 
black. Patient characteristics, including SES, are ascertained from in-home structured interviews 
administered by a nurse, who also gathered anthropomorphic information. Comorbidities, tumor 
characteristics, and treatment data are abstracted from medical record and pathology report 
documentation. Informed consent was obtained from all participants. All procedures performed 
in CBCS3 were in accordance with the ethical standards of the Institutional Review Board of the 
University of North Carolina at Chapel Hill. 
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 The study was conducted within the CBCS3 cohort of 2,998 women, between the ages of 
20 and 74 at the time of diagnosis, receiving a first, primary diagnosis of breast cancer between 
May 1, 2008 and October 21, 2013 and lived within the 44-county study area. The present 
analysis included 2,841 women. The study sample was restricted the analysis to stage I-III breast 
cancers and having received surgical treatment within 18 months of diagnosis. 
5.2.2 Covariate assessment 
 Interviewer-administered questionnaire and follow-up survey. Patients self-reported 
income, education, marital status, family history of breast cancer, insurance status and rural 
residence. We defined rural residence as population >10,000 vs. ≤10,000 people. A nurse 
measured height and weight in-home during the interview, which was used to define body mass 
index (BMI) as ≤25, 25-30, and >30 kg/m2. Job loss because of breast cancer diagnosis and 
inability to see a doctor because of financial and transportation issues were assessed via a 
telephone survey 18 months post-diagnosis.  
 Medical record review and pathology reports. Comorbidities (diabetes, heart disease and 
current smoker status) tumor size, nodal status, and grade data were abstracted from patients’ 
medical records.  Hormone receptor (HR), human epidermal growth factor receptor 2 (HER2), 
and Triple Negative breast cancer (TNBC) positivity data were ascertained from pathology 
reports.  
 Treatment modalities. Information on treatment type included surgery, radiation, and 
chemotherapy. Within each treatment type, the time to first and last treatment prior to recurrence 
of each was collected. Patients were grouped into four treatment modalities: surgery only, 
surgery and radiation, surgery and chemotherapy, and all three modalities.  
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 Patterns of SES, comorbidity, access and tumor factors. Person-centered groups of SES, 
access to care and tumor characteristics were accessed from individual-level observed data by 
latent classes analysis (LCA). LCA identifies unobservable, or latent, groups of individuals 
within a population based on numerical responses to observed set of factors (171). These 
subgroups are mutually exclusive and exhaustive. An iterative approach to parameter estimation 
using expectation-maximization (EM) for maximum-likelihood (ML) estimation generated 
estimates of all model parameters and item-response probabilities of class assignment. Here, we 
consider these three latent class groups as predictor groups of treatment delay (Table 5.5).  
5.2.3 Outcome assessment 
 We evaluated two outcomes reflecting treatment delay using dates from the medical 
record: delay in treatment initiation and prolonged treatment duration. Treatment initiation (in 
days) is the time between breast cancer diagnosis date to the first treatment (definitive surgery, 
chemotherapy or radiation). Treatment initiation was dichotomized as >60 days, based on 
clinical guidelines and previous literature (166). Treatment duration (in days) is the time interval 
between the date of first treatment and the date of last treatment (definitive surgery, 
chemotherapy or radiation). Treatment duration was stratified by modality and within each group 
the upper quartile of days was defined (radiation, 49 days; definitive surgery, 74 days; 
chemotherapy, 119 days) and duration of treatment was compared against other patients who 
received the same therapies. We defined prolonged treatment duration as women who were 
above the 75th percentile of treatment duration compared to others in their group. 
5.2.4 Statistical analysis  
 We identified latent classes of SES, barriers to care, and tumor characteristics using latent 
class analysis in SAS PROC LCA (209). We used several criteria to determine the number of 
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classes from the ML solution using many sets of starting values. We examined the G2 likelihood 
ratio test statistic produced using 100,000 sets of starting values, Akaike’s information criterion 
(AIC) and Bayesian Information Criterion (BIC), a goodness-of-fit measure to find more 
parsimonious models. Once the optimal model for parsimony and model fit was determined, 
individuals were assigned to the classes based their highest probability of membership. 
Generalized linear models were used to estimate relative frequency differences (RFDs) and 95% 
confidence intervals (95% CIs) as measures of association between 1) delay in treatment 
initiation greater than 60 days and 2) treatment duration measured in quartiles, and race, age and 
latent class patterns of individual-level SES, access to care, and tumor characteristics. 
Generalized linear models stratified by race were adjusted by age and models stratified by age 
were adjusted by race. We further estimated the association of treatment duration and race, age 
and latent class patterns of individual-level SES and access to care by treatment modalities. 
Lastly, we estimated the association of treatment duration and unadjusted single factors, both 
overall and by treatment modalities. All analyses were done in SAS version 9.4 (SAS Institute, 
Cary, NC). P-values were produced for a two-sided test with an alpha of 0.05 for statistical 
significance.  
5.3 Results 
 In the CBCS3 population, comprised of equal numbers of black and white women, 
median time to treatment initiation was 34 days (interquartile range: 19, 43). Overall, 10.6% 
delayed breast cancer treatment. Black women experienced greater delayed treatment (13.4% vs. 
7.9%) and more prolonged duration (29.9% vs. 21.1%) compared to white women (Table 5.1). 
Younger women experienced more prolonged duration (27.0% vs. 23.8%) compared to older 
women, but delayed treatment was similar to older women. Cross-classifying on race and age, 
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32.0% of younger black women experienced prolonged treatment duration compared to 22.3% of 
younger white women (Figure 5.1). Patterns of low SES, increasing barriers to care, and 
aggregated features of tumor aggressiveness were most strongly associated with prolonged 
treatment duration; only low SES and TNBC/higher grade tumor characteristics were associated 
with treatment initiation . Lastly, aggregated tumor factors by race were less associated with 
delay in treatment initiation but associated with prolonged duration, most pronounced among the 
HER2+/higher grade latent class; younger women experienced less delayed initiation with 
HER2+/higher grade and TNBC/higher grade latent classes (Table 5.6). 
 Data on SES and barriers to care latent classes and treatment initiation and duration by 
race are shown in Table 5.2. After adjusting for age, associations of race with treatment initiation 
and duration were statistically significant, with black women significantly more likely to 
experience both delayed treatment initiation and prolonged treatment duration. Compared to 
white women, the RFD for delayed treatment initiation among black women was 5.5% (95% CI: 
3.2%, 7.8%) and was 8.8% % (95% CI: 5.7%, 12.0%) for prolonged treatment duration. 
However with treatment initiation, when considering the race association stratified by the 
SES/comorbidity and access to care latent classes, the associations were attenuated and generally 
not statistically significant. Of note, the prevalence of delayed initiation among black women is 
high in the low SES/high comorbidity and more barriers to care latent classes (14.4% and 16.4%, 
respectively).  
 In contrast, the association of race and treatment duration is compounded by the 
SES/comorbidity and access to care latent classes. When considering the SES/comorbidity latent 
classes, the estimated RFDs were statistically significant and elevated similarly in both races 
(RFD for white and black women: 8.1%; 95% CI: 4.7%, 11.5% and 8.4%; 95% CI: 3.5%, 
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13.3%). We observed a substantially high magnitude among black and white women with more 
barriers to care; among women with increased barriers, the RFD for prolonged treatment 
duration for black women was 14.1% (95% CI: 6.5%, 21.8%) and for white women was 11.7% 
(95% CI: 5.5%, 17.8%). 
5.3.1 Treatment duration by treatment modalities 
 Given the variation in prolonged treatment duration disparity by race, age and SES and 
access latent classes, we examined these differences by treatment modalities (Table 5.3). Across 
all modalities, within each same treatment type, black women experienced greater prolonged 
treatment duration compared to white women. Across most modalities, low SES women 
experienced prolonged treatment duration compared to high SES. The most marked differences 
were in the more barriers to care group compared to less barriers to care; women who received 
surgery and radiation treatment (RFD = 21.2%; 95% CI: 5.1%, 37.2%) and surgery, radiation 
and chemotherapy (RFD = 16.0%; 95% CI: 7.9%, 24.0%) experienced greater prolonged 
treatment duration. 
5.3.2 Individual factors in prolonged treatment duration 
 To evaluate factors of SES and barrier to care latent classes, analyses on single factors 
and treatment duration were conducted (Table 5.4). Considering all treatment paths, prolonged 
treatment duration was associated with uninsured, financial and transportation issues. These 
individual factors persisted by difference treatment modalities. Financial issues among treatment 
modalities that included radiation and/or chemotherapy were statistically significant; the RFD for 
women with financial issues compared to no issues was 14.8% (95% CI: 2.4, 27.1) among 
surgery and radiation and 9.3% (95% CI: 3.1, 15.5) among the surgery, radiation and 
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chemotherapy modality. Lastly, transportation issues among modalities that included radiation 
therapy were strong statistically significant predictors of prolonged treatment duration. 
5.4 Discussion 
 In this population-based cohort of 2,841 women with stage I-III breast cancer, we found 
black race was associated with both delayed treatment initiation and prolonged treatment 
duration. While patterns of SES, barriers to accessing care and tumor characteristics among 
delayed treatment initiation were largely attenuated and not statistically significant, they 
persisted in strong associations with prolonged treatment duration by race. Black women with 
low SES and increased barriers to care also had significant proportions (32.9% and 42.6%, 
respectively) of prolonged treatment duration. When considering different treatment modalities, 
within each same treatment type, black women had more prolonged duration. Prolonged duration 
in women with low SES and increased barriers to care persisted as strong statistically significant 
predictors among most treatment paths, with increased barriers having the most marked 
differences in modalities that included radiation. Using latent class analyses to examine these 
SES and access to care in aggregate, we observed patterns in prolonged treatment duration that 
allowed us to examine individual modifiable factors that can be intervened on. We identified 
transportation as a key intervenable single factor that greatly increases prolonged treatment 
duration risk in treatment types that include radiation. 
 Our results are consistent with previous findings that race (210-214), as well as SES 
factors and insurance coverage (215-217) are associated with delayed treatment initiation and 
prolonged treatment duration. Black women are more likely to not complete or delay follow-up 
after abnormal screening result (218, 219). This disparity in delayed treatment has been 
explained by knowledge and beliefs, financial barriers, poor physician-patient communication 
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and system inefficiencies (168, 220-222). Other studies have shown associations between less 
social support, work-related limitations, and lower chemotherapy dosing among black patients 
(213, 223). Treatment for black patients is more likely to not be in accordance with established 
guidelines; black women are also more likely to have longer intervals and delays in surgical 
treatment, less and delayed radiation, and delayed and not completing chemotherapy (211, 213, 
224-226). Area-level access to healthcare for timely appropriate treatments differ by rural vs. 
rural areas (225, 227), which can compound racial differences in treatment duration and thus, 
mortality. It has also been noted that black women have lower rates of breast conserving surgery 
and breast reconstruction after mastectomy (228, 229), which are associated with adjuvant 
chemotherapy treatment delays (230). Compounding this among younger women, tumors are 
more likely to be more aggressive and less responsive to treatment (196, 199). More adverse 
tumor characteristics also associated with SES (200). Overall, we see that our observation of 
delayed treatment initiation by race is consistent with previous studies, but that it is also 
important to complete the treatment in a timely fashion. Our result that delays in treatment 
persist beyond treatment initiation into treatment duration may be because different treatment 
modalities have been optimized for certain dosing regimens with a certain amount of time and 
delays in duration can negatively affect the treatment plan. 
 Previous CBCS results have shown that financial factors impact treatment compliance 
(195). Radiation therapy, requiring more time, adds more complication to the treatment 
modality; more visits, more understanding of the treatments and more opportunities for issues to 
arise. We found that aggregated SES and financial barriers are impactful on prolonged treatment 
duration and more pronounced among black patients and treatment plans that include radiation 
therapy. The clear effects of both SES and barriers and race and age add to the recent work on 
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the importance of financial factors on treatment by race. When examining the association of 
single factors and prolonged treatment duration, we found that insurance, financial issues, and 
transportation issues were impactful. Gallups et al. found employment status and number of 
comorbidities significant predictors for total treatment delays among black women (231). 
However, length of treatment data were not available in this study. Previous interventions to 
reduce treatment delay have been implemented. The creation of cancer navigator programs and 
use of navigator positions to coordinate care of patients has improved timeliness of cancer care 
and reduced loss to follow up (232, 233). The coordination of multidisciplinary clinics has also 
been shown to decrease surgery delay by creating more access to timely treatment (214). 
 These findings should be interpreted with limitations in mind. One, we could not evaluate 
the long-term impact of prolonged treatment duration on survival. CBCS3 recruitment ended in 
2013, and has limited follow-up time and has not yet accrued enough person time for such 
analyses, especially given the median survival for breast cancer is 7 years. Future work should 
consider long-term survival as a function of prolonged treatment duration. Another limitation 
was the variables that created the barriers to care latent classes lacked detail. Greater resolution 
on financial and transportation issues would have allowed for interactions and useful subgroups 
analysis to evaluate, for example, where the transportation issues are most susceptible. This 
study has notable strengths, including quality individual level data on SES, access issues, and 
tumor characteristics, a large sample of black and young women and lastly, detailed treatment 
data by modality.  
5.5 Conclusion 
 Black race was associated with both delayed treatment initiation and prolonged treatment 
duration. While differences by treatment initiation according to SES and barriers existed, the 
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most profound differences were observed for treatment duration where black women with low 
SES and more barriers to care were more likely to be in the highest quartile of duration. Among 
different treatment modalities, within each same treatment type, black women had more 
prolonged duration compared to white women. We also observed prolonged treatment duration 
disparity persisted among women with low SES and among women with more barriers to care 
when considering different treatment modalities. The person-centered approach of latent class 
analysis revealed aggregated patterns of SES and barriers to care. The result allowed us to 
identify modifiable factors to intervene on among different treatment modalities. By estimating 
individual factors associated with prolonged treatment duration, we identified transportation 
issues as a priority factor that may have substantial impact, especially among treatments that 
include radiation therapy. These factors may be targetable for multi-level interventions; at the 
provider level with targeted messaging about the prolonged treatment duration among higher-







































Table 5.1. Treatment initiation and treatment duration by race, age and latent classes of SES and access to care in Carolina Breast 
Cancer Study 3 (2008-2013) 
 Treatment initiation  Treatment durationa 
 ≤60 days >60 days  Q1-3 Q4 
 No. (%) No. (%)  No. (%) No. (%) 
Raceb          
White 1333 (92.1) 115 (7.9)  1143 (78.9) 305 (21.1) 
Black 1206 (86.6) 187 (13.4)  976 (70.1) 417 (29.9) 
Black vs. white, RFD (95% CI) ref 5.5% (3.2, 7.8)  ref 8.8% (5.7, 12.0) 
Agec          
Older 1272 (89.3) 153 (10.7)  1086 (76.2) 339 (23.8) 
Younger 1267 (89.5) 149 (10.5)  1033 (73.0) 383 (27.0) 
Younger vs. older, RFD (95% CI) ref 0.3% (-1.9, 2.5)  ref 3.2% (0.1, 6.3) 
SES latent classesd          
High SES 1378 (91.6) 127 (8.4)  1192 (79.2) 313 (20.8) 
Low SES 1161 (86.9) 175 (13.1)  927 (69.4) 409 (30.6) 
Low vs. High, RFD (95% CI) ref 3.5% (1.2, 5.9)  ref 8.1% (4.7, 11.5) 
Access to care latent classesd          
Less Barriers to Care 2311 (89.8) 264 (10.2)  1954 (75.9) 621 (24.1) 
More Barriers to Care 227 (85.7) 38 (14.3)  164 (61.9) 101 (38.1) 
Low vs. high, RFD (95% CI) ref 2.8% (-1.6, 7.2)  ref 11.7% (5.5, 17.8) 
a Quartiles were separately defined by modality and Q4 was equal to 56, 74, 119 days for radiation, definitive 
surgery, and chemotherapy modalities, respectively 
b Multivariate models adjusting for age 
c Multivariate models adjusting for race 
a Multivariate models adjusting for race and age 







Table 5.2. Frequency of delayed treatment initiation and prolonged duration of treatment by race, and latent classes of SES and access 
to care in Carolina Breast Cancer Study 3 (2008-2013)a 
  Treatment initiation  Treatment durationb 
 
White  Black 
 
White  Black 
 
≤60 days >60 days  ≤60 days >60 days 
 
Q1-Q3 Q4  Q1-Q3 Q4 



















927 (93.3) 67 (6.7) 
 
451 (88.3) 60 (11.7) 
 
808 (81.3) 186 (18.7) 
 
384 (75.1) 127 (24.9) 
Low SES/High 
Comorbidity 
406 (89.4) 48 (10.6) 
 
755 (85.6) 127 (14.4)  335 (73.8) 119 (26.2) 
 
592 (67.1) 290 (32.9) 
















Access to Care latent 
classesc 
    
 






Less Barriers to 
Care 
1259 (92.2) 107 (7.8) 
 
1052 (87.0) 157 (13.0)  1084 (79.4) 263 (20.6) 
 
870 (72.0) 339 (28.0) 
More Barriers to 
Care 
74 (90.2) 8 (9.8) 
 
153 (83.6) 30 (16.4)  59 (71.9) 28 (28.1) 
 
105 (57.4) 78 (42.6) 
















a Multivariate models adjusting for age 
b Quartiles were separately defined by modality and Q4 was equal to 56, 74, 119 days for radiation, definitive surgery, and 
chemotherapy modalities, respectively  
c n=2840  








Table 5.3. Quartiles of duration among treatment modalities by race, age, SES, and barriers to care latent classes 
 Treatment durationa 

















 No. (%) No. (%)  No. (%) No. (%)  No. (%) No. (%)  No. (%) No. (%) 
Race                    
White 171 (78.8) 46 (21.2)  302 (77.4) 88 (22.6)  302 (77.4) 88 (22.6)  175 (81.8) 39 (18.2) 




















Age                    
Older 166 (79.4) 43 (20.6)  354 (74.8) 119 (25.2)  108 (69.7) 47 (30.3)  458 (77.9) 130 (22.1) 


































    
High SES 144 (77.4) 42 (22.6)  290 (78.2) 81 (21.8)  180 (79.7) 46 (20.3)  578 (80.1) 144 (19.9) 



































    
Less 
Barriers 
259 (75.7) 83 (24.3) 
 
465 (75.0) 155 (25.0) 
 
263 (74.9) 88 (25.1) 
 






 Treatment durationa 






















16 (61.5) 10 (38.5) 
 
21 (53.9) 18 (46.2) 
 
33 (73.3) 12 (26.7) 
 





















a n = 368, 659, 397, and 1417 for surgery only, surgery + radiation, surgery + chemotherapy, and surgery + radiation + chemotherapy, 
respectively 








Table 5.4. Individual factors of SES and barriers to care and prolonged duration of treatment by treatment modalities 
 Treatment durationa 













 No. (%) No. (%)  No. (%) No. (%)  No. (%) No. (%) 
Uninsured               
No 467 (74.3) 161 (25.6)  276 (74.2) 96 (25.8)  1000 (75.6) 323 (24.4) 














Financial issues                
No 425 (75.4) 139 (24.7)  229 (75.1) 76 (24.9)  812 (77.3) 239 (22.7) 














Transportation issues               
No 448 (74.8) 151 (25.2)  250 (76.0) 79 (24.0)  1124 (77.0) 381 (23.0) 














Job loss due to diagnosis                
No 472 (74.2) 164 (25.8)  284 (75.1) 94 (24.9)  1012 (75.2) 333 (24.8) 














a n = 368, 659, 397, and 1417 for surgery only, surgery + radiation, surgery + chemotherapy, and surgery + radiation + 
chemotherapy, respectively 








Table 5.5. Characterization of latent classes 
Class Class labels (%) Characterization 
SES High SES/low 
comorbidity  
(54%) Highest levels of income and education, being married, 
less diabetes, heart disease, and smoker status 
 Low SES/high 
comorbidity 
(46%)  
    
Access to care Less barriers (87%) Lower probabilities of being uninsured, job loss, and 
financial and transportation issues 
 More barriers (13%)  
    
Tumor Characteristics HR+/HER2-/node 
negative  
(40%) Highest probability of HR+ 
 HER2+/higher grade (10%) Highest probabilities of high grade and HER2+ 
 HR+/HER2-/larger 
tumor/node positive 
(29%) Highest probabilities of large tumor size and HR+ 









Table 5.6. Relative frequency of race, treatment initiation and treatment duration in Carolina Breast Cancer Study 3 (2008-2013)a 
  Treatment initiation  Treatment duration
b 
 
White  Black 
 




























No. (%) No. (%)  No. (%) No. (%)   No. (%) No. (%)  No. (%) No. (%) 
Tumor Characteristics latent 
classesc 
    
 










643 (91.9) 57 (8.1) 
 
351 (83.6) 69 (16.4) 
 
557 (82.4) 123 (17.6) 
 
309 (73.6) 111 (26.4) 
(2) HER2+/Higher 
Grade 
130 (93.5) 9 (6.5) 
 
152 (88.4) 20 (11.6) 
 
97 (69.8) 42 (30.2) 
 




372 (90.7) 38 (9.3) 
 
344 (83.3) 69 (16.7) 
 
315 (76.8) 95 (23.2) 
 
274 (66.3) 139 (33.7) 
(4) TNBC/Higher 
Grade 
188 (95.0) 10 (5.1) 
 
359 (92.5) 29 (7.5) 
 
153 (77.3) 45 (22.7) 
 
292 (75.3) 96 (24.7) 










































a Multivariate models adjusting for age 
b Quartiles were separately defined by modality and Q4 was equal to 49, 74, 119 days for radiation, definitive surgery, and chemotherapy 
modalities, respectively  
c n=2840  
Abbreviations: SES, socioeconomic status; HER2+, human epidermal growth factor receptor 2 positive; TNBC, triple negative breast cancer; 




CHAPTER 6: DISCUSSION 
6.1 Main findings 
 The aims of this dissertation were to: 1) develop an understanding of how various access 
and biology factors segregate in the population to develop a more complex picture of race and 
young aged breast cancer survivors and 2) estimate the association between SES, access to care 
patterns and treatment delay by race and age.  
 First, we found that major SES and comorbidity patterns in CBCS3 participants were 
generally similar to patterns in the state of North Carolina. The CBCS3 study population had 
slightly higher income, education and non-rural residence compared to the state. Compared to 
white women, black women were less likely to be married, in higher income strata, have rural 
residence and insurance and were more likely to be obese. Next, in CBCS3, we examined the 
distributions of individual tumor characteristics by race and age. Overall, older white women had 
the most favorable tumor characteristics, with more aggressive features seen for younger white 
women and for younger and older black women.  
 Next, we identified factor patterns of SES (2), barriers to care (2), and tumor 
characteristics (4), which reflected women with low and high SES, low and high comorbidities, 
increased and decreased barriers to healthcare and more aggressive tumor characteristics. We 
observed differences in these patterns by race and age; when controlling for the effect of age, 
black race was positively associated with low SES, more barriers to care, and more aggressive 
aggregated tumor characteristics compared to white women. Controlling for race, younger age 
was negatively associated with low SES, but positively associated with more barriers to care, and 
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more aggressive aggregated tumor characteristics.  Further cross-classification on race and age 
also showed these patterns. Taken together, these models suggest a compounding of high risk 
SES, access, and tumor biological factors for younger and black women. 
 Lastly, compared with high SES, less barriers to care and better prognosis tumor factor 
patterns, the low SES, increased barriers to care and worse prognosis tumor factor patterns were 
associated with prolonged treatment duration among black women. When stratified by treatment 
modality, black women, and women with low SES and increased barriers persisted in prolonged 
treatment duration disparity. By examining the aggregated patterns of SES and barriers to care, 
we identified possible modifiable factors to intervene on targeted within different treatment 
modalities. By estimating individual factors associated with treatment delay, we identified 
transportation issues as a priority factor that may have substantial impact as an individual 
modifiable driver of prolonged treatment duration, particularly among treatment types that 
include radiation therapy. 
6.2 Dimensionality reduction, person-centered approach to disparities research questions 
 The arc of this work began with an attempt to address the broader contextual issue around 
the complexity of race and age in health disparities research and disentangle the varying 
contributions of multifaceted and interactive biological and non-biological factors that influence 
inequitable breast cancer outcomes. To address this goal, we began with person-centered, 
dimensionality reduction analytical methods to more comprehensively characterize and 
understand this “social-contextual and biological mixture”. Dimensionality reduction allowed us 
to evaluate overall complex patterns that vary between people. We used latent class analysis, a 
person-oriented approached, which can be contrasted with a variable-oriented approach like 
factor analysis, where the emphasis is on identifying relations between variables and it is 
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assumed that these relations apply across all people. This method resulted in a more nuanced 
patterning in which to discriminate varying impacts. Here, we considered race as a social 
construct as well as a biological construct and attempted to disentangle how SES interacts with 
other types of barriers. Interactions of race and young age and social-contextual barriers, 
comorbidities and tumor factors helped to refine the analysis of breast cancer treatment delays. 
 A major limitation of data dimensionality reduction in breast cancer outcomes research is 
that while it can provide greater understanding of the relationality of factors, in the process it can 
reduce the underlying actionable public health impact. It is very difficult to change SES or all the 
components that comprise barriers to care. Thus, the arc of this work ended with inputting the 
probability data-driven patterns to reveal areas that could be intervenable. By understanding the 
patterns, we were able to evaluate what were the main drivers of the differences we observed. 
The result allowed us to look at individual factors that drive a substance absolute difference in 
treatment outcomes by treatment modality in order to define interventions specific for differing 
treatment modalities.  
6.3 Limitations and future directions  
 This study had limitations. Our study was limited to black and white women diagnosed 
with breast cancer living in North Carolina 2008 to 2013. As such, the results of this study may 
not be generalizable to women with breast cancer of other races/ethnicities or other geographic 
locations. In our analysis comparing the CBCS3 study population to the state of North Carolina, 
we were unable to restrict BRFSS to the same sampling regions used in CBCS3 due to the 
limitation of the restricted geographic information of the publicly available BRFSS data source. 
Another limitation was despite the large sample of younger and black women and the statistically 
significant associations we found by race and age, the precision of our estimates were limited. 
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Additionally, the analyses of SES and barriers to health care latent classes and treatment duration 
stratified by treatment modalities were limited in statistical power to detect differences by race 
and age. The variables that comprised the barriers to care latent class were limited; greater detail 
about financial and transportation issues would have aided in evaluating particular groups of 
women where these issues were most impactful. Another significant limitation of this study was 
that we could not evaluate the long-term impact of prolonged treatment duration on survival. 
CBCS3, which ended recruitment in 2013, has not yet accrued enough person time for such 
analyses. Lastly, we did not consider the role of mental health in construction of the latent 
classes.  
 There are a number of research questions that remain that future study can address.  
Future work should consider:  
1. Greater focus on access to care. More detailed questions about access to care may lead to 
improved interventions in accessing cancer care. We identified transportation as a single 
intervenable factor in access to care that is associated with prolonged treatment duration. 
Future study can further pinpoint patients with the greatest need for transportation 
assistance. This information could maximize hospital-level interventions, such as shuttle 
services for patients to and from appointments.  
2. Long-term survival as a function of prolonged treatment duration.   
3. And mental health covariates in latent class analyses and as potential indictors in 
treatment initiation and duration. 
6.4 Conclusion and public health impact 
 In sum, we considered race as a social construct as well as a biological construct in these 
analyses and attempted to disentangle how SES interacts with other types of barriers. We used a 
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high level view and saw how aggregating people gave us a better understanding of patterns of 
these factors and how they are associated with race. We combined the social determinants of 
health, the biological factors and breast cancer treatment modalities, to evaluate how these 
factors combine and contribute to differences by race in treatment delay. Lastly, we ultimately 
circled back to identifying individual factors that explained substantial proportions of the 
difference. More fully capturing and comprehensively disentangling the interaction and 
patterning of tumor biological factors, social determinates of health and the role of health 
services, using a probabilistic model-based approach, informed the public health impact in breast 
cancer disparities 1) to improve specific interventions targeting subgroups of women with breast 
cancer and 2) create messaging for clinicians to utilize and patients to understand increased risk 
of prolonged breast cancer treatment duration and importance of timely treatment among key 
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